Wolfgang Kern

Wolfgang Kern's AcademicInfluence.com Rankings

Wolfgang Kern

Physics

#5343

World Rank

#7164

Historical Rank

physics Degrees

Download Badge

Physics

Why Is Wolfgang Kern Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Wolfgang Kern's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes (2013) (1219)
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. (2002) (1010)
BRAF mutations in hairy-cell leukemia. (2011) (763)
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. (2005) (750)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. (2018) (689)
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. (2006) (387)
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients. (2008) (383)
Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping (2007) (331)
AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. (2003) (322)
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. (2009) (321)
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. (2009) (319)
Dynamics of clonal evolution in myelodysplastic syndromes (2016) (311)
Implications of NRAS mutations in AML: a study of 2502 patients. (2006) (299)
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. (2010) (299)
Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML (2004) (287)
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). (2012) (285)
Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles (2002) (283)
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. (2003) (281)
RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. (2011) (259)
The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. (2005) (256)
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. (2004) (252)
A novel hierarchical prognostic model of AML solely based on molecular mutations. (2012) (248)
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients (2014) (241)
Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. (1992) (240)
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype (2009) (236)
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. (2011) (232)
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. (2017) (226)
Landscape of TET2 mutations in acute myeloid leukemia (2012) (222)
New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. (2003) (219)
Global approach to the diagnosis of leukemia using gene expression profiling. (2005) (217)
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group (2012) (215)
Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. (2006) (211)
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes (2009) (205)
Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype (2008) (203)
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome (2013) (197)
IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. (2010) (195)
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. (2006) (190)
Monitoring of minimal residual disease in acute myeloid leukemia (2005) (187)
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. (2003) (183)
Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10 (2011) (181)
Adult acute myeloid leukaemia. (2004) (170)
Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile (2005) (169)
A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases (2011) (165)
Molecular characterization of acute leukemias by use of microarray technology (2003) (161)
SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations (2013) (157)
Prophylactic action of oral fluconazole against fungal infection in neutropenic patients (2000) (155)
The molecular profile of adult T‐cell acute lymphoblastic leukemia: Mutations in RUNX1 and DNMT3A are associated with poor prognosis in T‐ALL (2013) (150)
The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases (2017) (146)
The role of different genetic subtypes of CEBPA mutated AML (2014) (144)
A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. (2007) (142)
Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML (2010) (141)
Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance (2011) (141)
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups (2019) (141)
The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. (2004) (137)
Analysis of FLT 3 length mutations in 1003 patients with acute myeloid leukemia : correlation to cytogenetics , FAB subtype , and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease (2002) (137)
Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. (2004) (120)
Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. (2007) (119)
Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia (2011) (119)
Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes—proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS (2014) (116)
TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. (2014) (115)
Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: A detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24‐color FISH (2002) (114)
Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients (2004) (112)
2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. (2021) (112)
Frequency and causes of refractoriness in multiply transfused patients (1997) (111)
Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project (2015) (111)
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. (2022) (109)
High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome (2014) (109)
Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). (2010) (106)
Detailed analysis of FLT3 expression levels in acute myeloid leukemia. (2005) (101)
High‐dose cytosine arabinoside in the treatment of acute myeloid leukemia (2006) (100)
Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease (2014) (99)
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG (2009) (99)
New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes (2005) (99)
Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. (2001) (98)
Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee (2015) (95)
AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features (2009) (91)
Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison (1998) (91)
GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis (2013) (90)
Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia (2014) (88)
Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy. (2005) (88)
Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. (2003) (86)
Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E (2006) (85)
The role of multiparameter flow cytometry for disease monitoring in AML. (2010) (85)
STAT3 mutations are highly specific for large granular lymphocytic leukemia (2013) (82)
Diversity of the juxtamembrane and TKD1 mutations (Exons 13–15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data (2012) (81)
Landmark analysis of DNMT3A mutations in hematological malignancies (2013) (80)
FLT3 Length Mutations as Marker for Follow-Up Studies in Acute Myeloid Leukaemia (2004) (79)
Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome (2010) (79)
Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. (2005) (78)
Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies (2010) (78)
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions (2019) (78)
Stability of leukemia‐associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: Comparison with cytomorphologic, cytogenetic, and molecular genetic findings (2004) (76)
Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93% (2014) (76)
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party (2021) (75)
Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q (2005) (75)
Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients (2013) (74)
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera (2009) (72)
Subtype-specific patterns of molecular mutations in acute myeloid leukemia (2017) (72)
Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia. (2004) (72)
Modern diagnostics in acute leukemias. (2005) (72)
Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients (2001) (71)
Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis (2009) (71)
Impact of FLT3 mutations and promyelocytic leukaemia‐breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia (2005) (71)
WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups (2014) (69)
Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia (2011) (67)
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group (2012) (67)
AML with CBFB–MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions (2010) (67)
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes (2021) (66)
Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. (2020) (66)
Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. (2012) (66)
Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group (2017) (66)
Correlation of protein expression and gene expression in acute leukemia (2003) (66)
Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA (2011) (65)
Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia (1998) (65)
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. (2009) (65)
Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information (2005) (64)
Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations (2015) (63)
Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia. (2011) (60)
High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms (2013) (60)
NCAM (CD56)-positive malignant lymphoma. (1993) (60)
Robustness of amplicon deep sequencing underlines its utility in clinical applications. (2013) (59)
Diagnostic pathways in acute leukemias: a proposal for a multimodal approach (2007) (59)
Monoclonal B‐cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early‐stage CLL (2012) (57)
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. (2012) (57)
A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group. (2004) (56)
Genetic characterization of T‐PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker (2016) (56)
CEBPA double‐mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis (2013) (56)
Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics (2012) (56)
Application of an NGS‐based 28‐gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera (2016) (55)
Subclones with the t(9;22)/BCR‐ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations (2011) (55)
Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study of 124 patients (2002) (54)
Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters (2010) (53)
High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias (1997) (53)
NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse. (2018) (53)
Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category (2009) (52)
SOX11 overexpression is a specific marker for mantle cell lymphoma and correlates with t(11;14) translocation, CCND1 expression and an adverse prognosis (2013) (52)
Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients (2007) (51)
Oxaliplatin pharmacokinetics during a four-hour infusion. (1999) (51)
Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology. (2011) (51)
ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events (2012) (50)
The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers (2007) (50)
High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia (2013) (49)
Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome (2014) (49)
Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia (2012) (48)
Gene expression profiling as a tool for the diagnosis of acute leukemias. (2003) (48)
Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells (2011) (48)
Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS) (2010) (48)
AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes (2005) (47)
Treatment of older patients with AML. (2005) (47)
BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia (2014) (46)
An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling (2011) (46)
Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact (2014) (46)
Targeted next-generation sequencing detects point mutations, insertions, deletions and balanced chromosomal rearrangements as well as identifies novel leukemia-specific fusion genes in a single procedure (2011) (46)
Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia (2016) (46)
Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML (2019) (45)
Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. (2005) (44)
Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization. (2004) (43)
Pattern robustness of diagnostic gene expression signatures in leukemia (2005) (43)
Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma (2004) (42)
IDH 1 mutations are detected in 6 . 6 % of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM 1 status (2010) (42)
Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients (2005) (42)
Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia (2016) (41)
Harmonemia: a universal strategy for flow cytometry immunophenotyping—A European LeukemiaNet WP10 study (2016) (40)
The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML (2011) (40)
Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis (2008) (39)
Evaluation of complete disease remission in acute myeloid leukemia (2006) (39)
JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML (2007) (39)
Impact of trisomy 8 on expression of genes located on chromosome 8 in different AML subgroups (2006) (39)
Clinical Utility of Multiparameter Flow Cytometry in the Diagnosis of 1013 Patients with Suspected Myelodysplastic Syndrome: Correlation to Cytomorphology, Cytogenetic, and Clinical Data. (2009) (38)
Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1 (2013) (38)
Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2 (2018) (36)
Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia (2001) (36)
Acute myeloid leukemia with recurring chromosome abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute myeloid leukemia. (2003) (36)
Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms (2011) (35)
The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic/myeloproliferative neoplasms (2018) (34)
Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics (2013) (33)
Insight into the molecular pathogenesis of myeloid malignancies (2007) (33)
Correlation of flow cytometrically determined expression of ZAP‐70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia (2009) (33)
Several lymphoma‐specific genetic events in parallel can be found in mature B‐cell neoplasms (2011) (32)
Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes (2017) (32)
Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution (2003) (32)
Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment (2010) (31)
Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases (2012) (31)
Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML (2018) (31)
Complex Landscape of Alternative Splicing in Myeloid Neoplasms (2020) (31)
Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms (2016) (30)
Quantification of rare NPM1 mutation subtypes by digital PCR (2014) (30)
Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia (2015) (30)
Enhancer hijacking drives oncogenic BCL11B expression in lineage ambiguous stem cell leukemia. (2021) (29)
Mutations of the TP53 Gene Occur in 13.4% of Acute Myeloid Leukemia and Are Strongly Associated with a Complex Aberrant Karyotype. (2006) (28)
The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia. (2005) (28)
JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases (2007) (28)
The new provisional WHO entity ‘RUNX1 mutated AML' shows specific genetics but no prognostic influence of dysplasia (2016) (28)
Genetic classification of acute myeloid leukemia (AML). (2004) (27)
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases (2012) (27)
Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia. (2004) (27)
Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow (2012) (26)
Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells (2011) (26)
TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele (2012) (26)
D324N single‐nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias (2006) (26)
Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B‐cell neoplasms (2010) (26)
AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients. (2015) (26)
Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin’s lymphoma – phase I/II studies and pharmacokinetics (1998) (26)
Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia (2007) (25)
Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection. (2000) (25)
Cisplatin nephrotoxicity in children after continuous 72-h and 3×1-h infusions (2001) (25)
Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene (2014) (25)
Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia (2010) (24)
Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia (1998) (24)
Rapid diagnostic approach to PML-RARalpha-positive acute promyelocytic leukemia. (2002) (24)
Deletion of the tumor-suppressor gene NF1 occurs in 5% of myeloid malignancies and is accompanied by a mutation in the remaining allele in half of the cases (2012) (24)
Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype. (2012) (24)
CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia (2011) (24)
Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML. (2010) (23)
A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia. (2006) (23)
Flow cytometric identification of 76 patients with biclonal disease among 5523 patients with chronic lymphocytic leukaemia (B‐CLL) and its genetic characterization (2014) (23)
Planning of Workstations in a Modular Automotive Assembly System (2016) (23)
Frequency and Prognostic Impact of CEBPA Proximal, Distal and Core Promoter Methylation in Normal Karyotype AML: A Study on 623 Cases (2013) (22)
Monitoring of acute myeloid leukemia by flow cytometry (2003) (22)
Detection of recurrent and of novel fusion transcripts in myeloid malignancies by targeted RNA sequencing (2018) (22)
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias (2001) (22)
The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: Ready for prime time? (2020) (21)
A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98–NSD1 fusion gene (2013) (21)
How artificial intelligence might disrupt diagnostics in hematology in the near future (2021) (21)
BRCC3 mutations in myeloid neoplasms (2015) (21)
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. (1996) (20)
Hematologist‐Level Classification of Mature B‐Cell Neoplasm Using Deep Learning on Multiparameter Flow Cytometry Data (2020) (20)
Molecular landscape of acute promyelocytic leukemia at diagnosis and relapse (2017) (20)
Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients (2015) (20)
Leukaemic blasts differ from normal bone marrow mononuclear cells and CD34+ haemopoietic stem cells in their metabolism of cytosine arabinoside (1999) (20)
Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukaemia (2015) (19)
Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies (2021) (19)
Cytidine deaminase – the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells (1999) (19)
The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes (2009) (19)
Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration (2021) (18)
Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile (2018) (18)
IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies (2018) (18)
EZH2 mutations and their association with PICALM‐MLLT10 positive acute leukaemia (2012) (18)
Evaluation of flow cytometric assessment of myeloid nuclear differentiation antigen expression as a diagnostic marker for myelodysplastic syndromes in a series of 269 patients (2012) (18)
Expression of CEBPA is reduced in RUNX1-mutated acute myeloid leukemia (2012) (17)
Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients (2018) (17)
Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity (2009) (16)
The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside‐based treatment regimens in acute myeloid leukaemia with a high proliferative activity (2000) (16)
Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDS. (2020) (16)
BCR‐ABL1‐positive and JAK2 V617F‐positive clones in 23 patients with both aberrations reveal biologic and clinical importance (2017) (16)
Clinical relevance of clonal hematopoiesis in the oldest-old population. (2021) (16)
Impact of integrating clinical and genetic information (2001) (16)
Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN (2016) (15)
Array CGH identifies copy number changes in 11% of 520 MDS patients with normal karyotype and uncovers prognostically relevant deletions (2016) (15)
Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve (2001) (15)
Feasibility of BAALC gene expression for detection of minimal residual disease and risk stratification in normal karyotype acute myeloid leukaemia (2016) (15)
Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups (2013) (15)
An Integrated Logistics Concept for a Modular Assembly System (2017) (15)
The kinetics of relapse in DEK‐NUP214‐positive acute myeloid leukemia patients (2015) (15)
Mixed Phenotype Acute Leukemia, T/Myeloid, NOS (MPAL-TM) Has a High DNMT3A Mutation Frequency and Carries Further Genetic Features of Both AML and T-ALL: Results of a Comprehensive Next-Generation Sequencing Study Analyzing 32 Genes (2012) (15)
Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma. (2010) (15)
Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML (2010) (15)
Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia (2012) (15)
Successful modulation of high‐dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine (2000) (15)
Gene expression profiling for the diagnosis of acute leukaemia (2006) (15)
Acute Myeloid Leukemia Following Treatment with Cladribine for Hairy Cell Leukemia: A Case Report and Review of the Literature (2004) (15)
Molecular patterns in cytopenia patients with or without evidence of myeloid neoplasm—a comparison of 756 cases (2018) (15)
Interactive diagnostics in the indication to allogeneic SCT in AML (2009) (15)
Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia. (2007) (14)
Three Steps to the Diagnosis of Adult Ph-like ALL (2015) (14)
Reverse transcriptase-polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemia (2006) (14)
Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. (2012) (14)
Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells. (1996) (14)
DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern (2019) (14)
Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia. (2013) (14)
MYC rearranged B-cell neoplasms: Impact of genetics on classification. (2016) (13)
Multiparameter flow cytometry reveals myelodysplasia‐related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms (2013) (13)
Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry to define leukemia-associated immunophenotypes and determine their frequencies in normal bone marrow (2003) (13)
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party (2021) (12)
Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification. (2021) (12)
Molecular subtypes of NPM 1 mutations have different clinical profiles , specific patterns of accompanying molecular mutations and varying outcome in intermediate risk acute myeloid leukemia (2015) (12)
Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative Group. (1998) (12)
Inverted duplication dup(1)(q32q21) as sole aberration in lymphoid and myeloid malignancies. (2009) (12)
Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22). (2006) (12)
Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity. (2002) (12)
Detection of Three Different MPLW515 Mutations in 10.1% of All JAK2 V617 Unmutated ET and 9.3% of All JAK2 V617F Unmutated OMF: A Study of 387 Patients. (2007) (12)
A new case with rare e6a2 BCR–ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment (2008) (11)
Gain of chromosome 21 or amplification of chromosome arm 21q is one mechanism for increased ERG expression in acute myeloid leukemia (2016) (11)
Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European LeukemiaNet (2021) (11)
A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls. (2011) (11)
Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia (2017) (11)
Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease (2018) (11)
Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias (2006) (11)
Flow cytometry in the diagnosis of myelodysplastic syndromes and the value of myeloid nuclear differentiation antigen (2014) (11)
Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics (2011) (11)
Characterization of a new myeloid leukemia cell line with normal cytogenetics (CG-SH). (2009) (11)
Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes. (2010) (11)
The landscape of myeloid neoplasms with isochromosome 17q discloses a specific mutation profile and is characterized by an accumulation of prognostically adverse molecular markers (2015) (11)
Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS‐Flow Cytometry Working Group (2021) (10)
Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia. (2019) (10)
Meeting report: Vienna 2008 Workshop of the German–Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes (2009) (10)
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myeloproliferative / myelodysplastic disorders : an analysis of 636 cases (2012) (10)
Mutations of the TP53 Gene Play an Important Role in the Pathogenesis of Acute Myeloid Leukemia with Complex Aberrant Karyotype. (2004) (9)
Initial flow cytometric evaluation of the Clearllab lymphoid screen (2018) (9)
Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia. (2010) (9)
Evaluation Of Different NPM1 Mutations In AML Patients According To Clinical, Cytogenetic and Molecular Features and Impact On Outcome (2013) (9)
Detailed molecular analysis and evaluation of prognosis in cases with high grade B‐cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (2018) (9)
A multicenter study evaluation of the ClearLLab 10C panels (2020) (9)
Amplification of EVI1 on cytogenetically cryptic double minutes as new mechanism for increased expression of EVI1. (2014) (9)
Hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer: role of carcino-embryonic antigen in assessment of response. (2000) (9)
ELN iMDS flow working group validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry (2021) (9)
Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia (2021) (8)
ASXL1 exon 12 Mutations Are Frequent in AML with Intermediate Risk Karyotype and Are Independently Associated with An Extremely Poor Outcome (2011) (8)
An Analytical Framework for Handling Production Time Variety at Workstations of Mixed-model Assembly Lines (2016) (8)
Gene Expression Profiling as a Diagnostic Tool in Acute Myeloid Leukemia (2004) (8)
Molecular mutations are prognostically relevant in AML with intermediate risk cytogenetics and aberrant karyotype (2013) (8)
Array-based comparative genomic hybridization detects copy number variations with prognostic relevance in 80% of ALL with normal karyotype or failed chromosome analysis (2016) (8)
Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age (2022) (8)
Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. (2022) (8)
Prognostic Impact and Landscape of NOTCH 1 Mutations in Chronic Lymphocytic Leukemia ( CLL ) : a Study on 852 Patients Letter to the Editor Chronic lymphocytic leukemia (2013) (8)
“Somatic” and “pathogenic” - is the classification strategy applicable in times of large-scale sequencing? (2019) (8)
The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations (2016) (8)
Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 75% of Chronic Myelomonocytic Leukemia (CMML) by Detecting Frequent Alterations in TET2 , RUNX1 , CBL , and RAS . (2009) (8)
Analyses of 81 Chronic Myelomonocytic Leukemia (CMML) for EZH2, TET2, ASXL1, CBL, KRAS, NRAS, RUNX1, IDH1, IDH2, and NPM1 Revealed Mutations In 86.4% of All Patients with TET2 and EZH2 Being of High Prognostic Relevance (2010) (8)
IDH1 Mutations Are Detected in 9.3% of All AML and Are Strongly Associated with Intermediate Risk Karyotype and Unfavourable Prognosis: a Study of 999 Patients (2009) (8)
Role of gene expression profiling for diagnosing acute leukemias. (2005) (7)
Detection of t(14;18)(q32;q21) in B-cell chronic lymphocytic leukemia. (2005) (7)
Chromosome Banding Analysis, FISH and RT-PCR Performed in Parallel in Hypereosinophilic Syndrome Establishes the Diagnosis of Chronic Eosinophilic Leukemia in 22% of Cases: A Study on 40 Patients. (2004) (7)
SRSF2 is Mutated in 47.2% (77/163) of Chronic Myelomonocytic Leukemia (CMML) and Prognostically Favorable in Cases with Concomitant RUNX1 mutations (2011) (7)
Molecular Classification of AML-MRC Reveals a Distinct Profile and Identifies MRC-like Patients with Poor Overall Survival (2019) (7)
Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia: results of a prospective multicenter phase II trial (1998) (7)
Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population (2020) (7)
Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial. (2009) (7)
Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count (2020) (7)
SF3B1 Mutations Have Adverse Impact On Time to Treatment Especially in Patients with 13q Deletions: A Study On 1,124 Chronic Lymphocytic Leukemia (CLL) Patients (2012) (6)
Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations (2019) (6)
Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia (2005) (6)
Monitoring of Minimal Residual Disease Using Next-Generation Deep-Sequencing in 460 Acute Myeloid Leukemia Cases identifies RUNX1 Mutated Patients with Resistant Disease (2011) (6)
RQ‐PCR based WT1 expression in comparison to BCR‐ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib‐treated chronic myeloid leukaemia (2009) (6)
CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk (2022) (6)
Cyclin D1 (CCND1) messenger RNA expression as assessed by real-time PCR contributes to diagnosis and follow-up control in patients with mantle cell lymphoma. (2013) (6)
Ultra-Deep Next-Generation Sequencing Detects RUNX1 Mutations with Unprecedented Sensitivity and Allows to Monitor Minimal Residual Disease In 116 Samples From MDS and AML Patients (2010) (6)
SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (2021) (6)
Comprehensive analysis of the genetic landscape of 21 cases with blastic plasmacytoid dendritic cell neoplasm by whole genome and whole transcriptome sequencing (2021) (6)
Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and de novo acute myeloid leukemia (2017) (6)
RT-PCR-Based MRD Detection in NPM1 Mutated AML: A Prospective Follow-Up Study in 130 Patients. (2007) (6)
Molecular characterization of a second myeloid neoplasm developing after treatment for acute myeloid leukemia (2019) (6)
Cytogenetic Clonal Evolution in MDS Is Associated with Shifts towards Unfavorable Karyotypes According to IPSS and Shorter Overall Survival: A Study on 988 MDS Patients Studied Sequentially by Chromosome Banding Analysis (2011) (6)
Differences in prognosis of stereotyped IGHV3-21 chronic lymphocytic leukaemia according to additional molecular and cytogenetic aberrations (2016) (6)
In AML Secondary to MDS NPM1 Mutations Are Late Events, Less Frequent, and Associated with a Different Pattern of Molecular Mutations Than in De Novo AML (2014) (6)
STAT3 Mutations in Large Granular Lymphocytic Leukemia (2012) (6)
Screening for TP53 Mutations Identifies Chronic Lymphocytic Leukemia Patients with Rapid Disease Progression. (2007) (6)
A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia. (2007) (6)
Knowledge transfer to enhance the performance of deep learning models for automated classification of B cell neoplasms (2021) (5)
Inhibition of PLK1 by capped‐dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis (2019) (5)
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. (1997) (5)
Dark-matter matters: Discriminating subtle blood cancers using the darkest DNA (2019) (5)
Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations (2015) (5)
Hepatic artery infusion of 5-fluorouracil, folinic acid plus oxaliplatin for liver metastasis from colorectal cancer. Final analysis of a phase I/II studay (2005) (5)
An international multi-center study to assess the clinical accuracy of the molecular subclassification of leukemia by gene expression profiling. (2006) (5)
Comprehensive study on ERG gene expression in normal karyotype acute myeloid leukemia: ERG expression is of limited prognostic value, whereas the accumulation of adverse prognostic markers stepwise worsens the prognosis (2016) (5)
Recurrent ATM and BIRC3 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) and Deletion 11q22-q23 (2012) (5)
[Diagnostics of acute leukemias: interaction of phenotypic and genetic methods]. (2012) (5)
The Role of Different Genetic Subtypes In CEBPA Mutated AML (2010) (5)
The AML1-ETO Fusion Gene and the FLT3 Length Mutation Collaborate in Inducing Acute Leukemia in a Murine Bone Marrow Transplantation Model. (2005) (5)
The Potential of Molecular Genetic Analysis for Diagnostic and Prognostic Decision Making in Clonal Cytopenia of Undetermined Significance (CCUS) and MDS - a Study on 576 Patients (2020) (4)
Correlation of Flow Cytometrically Determined Expression of ZAP-70 Using Two Different Antibodies with IgVH Mutation Status and Cytogenetics in 539 Patients with Chronic Lymphocytic Leukemia. (2006) (4)
MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations (2016) (4)
Impact of genetic alterations in stem-cell transplantation for myelodysplasia and secondary acute myeloid leukemia Short title: Genetic alterations in myelodysplasia with HCT (2017) (4)
Molecular Analyses of MDS/MPN Overlap Entities According to WHO Classification Reveal a Distinct Molecular Pattern for MDS/MPN, Unclassifiable (2014) (4)
New insights into the biology of acute myeloid leukemia and their impact on treatment. (2003) (4)
Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. (2005) (4)
Minimal Residual Disease in Patients with Acute Myeloid Leukemia Quantified by Multiparameter Flow Cytomety and Quantitative RT-PCR Is an Independent Prognostic Parameter. (2004) (4)
Evidence of clonality in cases of hypereosinophilia of undetermined significance (2019) (4)
PF532 INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (2019) (4)
AML with CBFB-MYH11 Rearrangement Is Characterized by RAS Pathway Alterations in 92% of Cases and Demonstrates a High Frequency of NF1 Deletions. (2009) (4)
An Artificial Intelligence (AI) Approach for Automated Flow Cytometric Diagnosis of B-Cell Lymphoma (2018) (4)
Older Age Is An Independent Risk Factor in AML (2008) (4)
RUNX1 Mutations in Normal Karyotype MDS Cooperate with Class I Mutations in the Progression to S-AML Following MDS. (2008) (4)
NRAS mutations in AML: biology, cytogenetics, and prognosis a study on 2502 patients (2006) (4)
Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes (2019) (4)
A Novel Machine Learning Based in silico Pathogenicity Predictor for Missense Variants in a Hematological Setting (2019) (4)
First Results of a 31-Gene Panel Targeted to Investigate Myeloid Malignancies by Next-Generation Amplicon Deep-Sequencing (2012) (4)
Superiority of High-Dose over Intermediate-Dose Cytosine Arabinoside (AraC) in the Treatment of Patients with High-Risk Acute Myeloid Leukemia (AML) (1998) (4)
Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases (2014) (4)
SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis (2022) (4)
AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics (2022) (4)
RUNX1 mutations in MDS, s-AML, and de novo AML: differences in accompanying genetic alterations and outcome (2019) (4)
RUNX1 Mutations Can Be Found in 34% of De Novo AML with Normal Karyotype or Single Chromosomal Imbalances and Are Associated with Good Prognosis but Turn to Unfavourable Outcome If Further Cytogenetic or Molecular Mutations Are Acquired (2008) (4)
Gene Expression Profiling in AML and MDS Identifies Genes Located on 5q Which Are Consistently Lower Expressed in Cases with 5q Deletion as Compared to Cases with Normal Karyotype. (2004) (4)
CML Patients with Resistance to Tyrosine Kinase Inhibitors and without BCR-ABL1 Resistance Mutation Frequently Carry Other Gene Mutations (2014) (4)
Characterization of MYD88 mutated Lymphoplasmacytic Lymphoma in Comparison to MYD88 mutated Chronic Lymphocytic Leukemia (2015) (3)
Accumulation of Somatic Mutations As a Function of Aging: A Study on 4843 TET2 Mutated Patients in Comparison to Their Respective SNP Pattern (2015) (3)
Automated Peripheral Blood Cell Differentiation Using Artificial Intelligence - a Study with More Than 10,000 Routine Samples in a Specialized Leukemia Laboratory (2021) (3)
An Artificial Neural Network Providing Highly Reliable Decision Support in a Routine Setting for Classification of B-Cell Neoplasms Based on Flow Cytometric Raw Data (2019) (3)
Myelodysplastic Syndromes (MDS) With 20q Deletion Show a High Frequency Of Associated Cytogenetic and Molecular Lesions With An Association To U2AF1, SRSF2, and Prognostically Adverse ASXL1 Mutations (2013) (3)
Multiparameter Flow Cytometry Provides Independent Prognostic Information in Patients with Suspected Myelodysplastic Syndromes: A Study on 804 Patients. (2016) (3)
Prognostic Impact of FLT3 Mutation Load in NPM1 Mutated AML. (2009) (3)
Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AML (2015) (3)
3′ Position of the FLT3-LM and Loss of Heterozygosity Are Highly Correlated to Unfavourable Outcome in AML. (2006) (3)
Treatment of AML in biological subgroups (2005) (3)
Trisomy 13 Defines a Subgroup of Myeloid Malignancies with an Extremely High Frequency of AML1 Gene Mutations and Newly Defined VEGFR-1 Mutations. (2006) (3)
Artificial Intelligence Substantially Supports Chromosome Banding Analysis Maintaining Its Strengths in Hematologic Diagnostics Even in the Era of Newer Technologies (2020) (3)
Molecular analysis of RAS-RAF tyrosine-kinase signaling pathway alterations in patients with plasma cell myeloma (2012) (3)
SF3B1 Mutations Are Detectable in 48.9% of Acute Myeloid Leukemia with Normal Karyotype (AML-NK) and ≥15% Ring Sideroblasts and Are Closely Related to FLT3-ITD and RUNX1 Mutations (2012) (3)
Diagnostic and Prognostic Utility Of a 26-Gene Panel For Deep-Sequencing Mutation Analysis In Myeloid Malignancies (2013) (3)
FISH-Diagnostik bei hämatologischen Neoplasien FISH diagnostics in hematological malignancies (2005) (3)
Determination of Minimal Residual Disease in Patients with Acute Myeloid Leukemia by Multiparameter Flow Cytometry: Prognostic Impact at Different Checkpoints. (2004) (3)
Categorizing Molecular Mutations in MDS and AML (2015) (3)
Machine Learning (ML) Can Successfully Support Microscopic Differential Counts of Peripheral Blood Smears in a High Throughput Hematology Laboratory (2020) (3)
Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses (2018) (3)
SOX11 over-Expression Is a Specific Marker for Mantle Cell Lymphoma and Correlates with t(11;14) Translocation, CCND1 Expression, and an Adverse Prognosis. (2012) (3)
Mutations of TET2 and JAK2 but Not CBL Are Detectable in a High Portion of Patients with Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T). (2009) (3)
Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML (2021) (3)
Cooperating Molecular Mutations in AML1/RUNX1 Mutated AML Differ Dependent on the Cytogenetic Subgroup. (2007) (3)
AraC Metabolism in Fresh Leukemic Blasts/ Normal Bone Marrow/ Hematopoetic Stem Cells and its Impact on the Lipid Composition of Leukemic Cells (HL60) (1998) (3)
Gene Amplifications Are Rare Events in AML and MDS and Are Associated with Complex Karyotype, TP53 Deletions and Very Poor Survival (2011) (3)
DNMT3A is a Powerful Follow-up Marker in NPM1 mutated AML (2014) (3)
Artificial intelligence in hematological diagnostics: Game changer or gadget? (2022) (3)
Failure of Fluconazole Prophylaxis to Reduce Mortality During Treatment for Refractory Acute Myeloid Leukemia: Results of a Phase III Multicenter Study (1998) (3)
Chronic systemic aspergillosis in a patient with acute myeloid leukemia (1998) (3)
Complex Aberrant Karyotypes and Unbalanced Translocations in CLL Correlate with an Unmutated IgVH Status: A Study on 133 Patients Studied with Chromosome Banding Analysis, Interphase FISH, IgVH Mutation Status, ZAP-70 RNA Expression and Immunophenotyping. (2005) (3)
Integrated Diagnostic Approach for Suspected Myelodysplastic Syndrome As a Basis for Advancement of Diagnostic Criteria (2016) (3)
Analysis of Mechanisms of Blast Crisis in Chronic Myeloid Leukemia By Whole Genome Sequencing (2020) (3)
Mutational Screening Of CSF3R, ASXL1, SETBP1, and SRSF2 In Chronic Neutrophilic Leukemia (CNL), Atypical CML and CMML Cases (2013) (3)
Genetic Patterns of Relapsed AML Differ Significantly from First Manifestation and Are Dependent on Cytogenetic Risk Groups at Diagnosis: Results in 175 Patients with Paired Samples (2014) (3)
Monoclonal B-Cell Lymphocytosis (MBL) Is Closely Related to Chronic Lymphocytic Leukemia (CLL) and May Be Better Classified as Early-Stage CLL. (2009) (3)
Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q (2022) (3)
Emissions at Coke Plants: European Environmental Regulations and Measures for Emission Control (2013) (3)
Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all demonstrating more than 50 % of bone marrow erythropoietic cells (2011) (2)
Modulation of the Clonal Composition in Relapsed CLL: A Study Based on Targeted Deep-Sequencing of ATM, BIRC3, NOTCH1, POT1, SF3B1, SAMHD1 and TP53 (2015) (2)
Minimal Residual Disease Assessed by NPM1 Mutation Specific RQ-PCR Is the Most Relevant Prognostic Parameter in NPM1-Mutated AML and Highly Useful to Guide Therapy (2008) (2)
IGHV Mutation Status Does Not Add Prognostic Information In The Background Of Mutations In TP53 and SF3B1, and Deletions Of 17p and 11q, Which Are Independent Adverse Prognostic Parameters In CLL (2013) (2)
A robust molecular pattern for myelodysplastic syndromes in two independent cohorts investigated by next‐generation sequencing can be revealed by comparative bioinformatic analyses (2014) (2)
Prognostic Factors in CBFB-MYH11 Positive AML: Trisomy 21, AGE, and t(16;16) Are Associated with Inferior Outcome. (2005) (2)
Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone (1996) (2)
Nucleophosmin Gene Mutations Are Predictors of Favourable Prognosis in Acute Myeloid Leukemia with a Normal Kayotype and Can Be Used as a New Marker for Quantitative PCR To Detect Minimal Residual Disease. (2005) (2)
Role of CEBPA-Mutations in AML with Prognostically Intermediate Cytogenetics: Data of the AMLCG Study Group and Gene Expression Analyses. (2004) (2)
The TP53 Codon72 Polymorphism Is Associated with TP53 Mutations in Chronic Lymphocytic Leukemia (2011) (2)
Prognosis of Mecom(EVI1)- rearranged MDS and AML Patients Strongly Depends on Accompanying Molecular Mutations but Not on Blast Counts (2015) (2)
Deep Learning Algorithms Support Distinction of PV, PMF, and ET Based on Clinical and Genetic Markers (2017) (2)
Knowledge Transfer between Artificial Neural Networks for Different Multicolor Flow Cytometry Protocols Improves Classification Performance for Rare B-Cell Neoplasm Subtypes (2019) (2)
Recurrent Mutations of the C-C Motif Chemokine Ligand 22 (CCL22) Define a Distinct Subgroup of Chronic Lymphoproliferative Disorder of NK Cells (CLPD-NK) (2020) (2)
Transcriptional Profiling Identifies Genes Differentially Regulated by the BCR/ABL Fusion Oncogene. (2004) (2)
Distinct, Ethnic, Clinical, and Genetic Characteristics of Myelodysplastic Syndromes with Der(1;7) (2019) (2)
PPM1D and DNMT3A Mutations in Myelodysplasia and Clonal Hematopoiesis (2019) (2)
FLT3 Length Mutations and MLL-Duplications in AML: Correlation to Cytogenetics, FAB-Subtype,and Prognosis (2003) (2)
High FLT3 mRNA Expression in Acute Myeloid Leukemia May Be Functionally an Alternative to Mutational Activation of the Receptor. (2004) (2)
Gene Expression Profiling Identifies a Prognostically Favorable Subgroup in AML Independent of Cytogenetic Stratification. (2004) (2)
Enhancer Hijacking of BCL11B Defines a Subtype of Lineage Ambiguous Acute Leukemia (2020) (2)
JAK2V617F as a Cooperative Mutation in AML with Trisomy 8 and t(8;21): A Comparative Study on 271 AML and 1103 CMPD Cases. (2006) (2)
Sole Trisomy 8 in AML: Concomitant Molecular Markers, Stability of Genetic Patterns and Impact On Outcome. (2012) (2)
Development of An Oligonucleotide Resequencing Array for Rapid Mutation Analysis in Acute Myeloid Leukemia with Normal Karyotype. (2009) (2)
Classification of AML by DNA-oligonucleotide microarrays. (2006) (2)
Flow Cytometric Determination of ZAP-70 Expression by SBZAP Antibody: Impact of Type of Data Analysis on Correlation with IgVH Mutation Status, Cytogenetics, and Level of ZAP-70 mRNA Expression in 351 Patients with Chronic Lymphocytic Leukemia (CLL). (2007) (2)
Impact of 9q deletions on the classification of patients with acute myeloid leukemia (2019) (2)
Diagnostic Value of CD200 Expression for the Differentiation Between Chronic Lymphocytic Leukemia (CLL), CLL with Increased Prolymphocytes (CLL/PL) and Mantle Cell Lymphoma. (2012) (2)
Evaluation of the New Genetic Risk Classification of the European LeukemiaNet Recommendations in 1,110 Patients with De Novo AML and Proposal of a Refined Version (2011) (2)
Identification of Biologically Distinct and Clinically Relevant Subentities in Patients with Acute Myeloid Leukemia and Normal Karyotypes by Use of Gene Expression Profiling. (2004) (2)
Interplay of TP53 Allelic State, Blast Count and Karyotype on Survival of Patients with AML and MDS (2022) (2)
Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group (2021) (2)
Comprehensive molecular characterization of myeloid malignancies with 9q deletion (2019) (2)
Flow cytometry in the diagnosis of myelodysplastic syndromes (MDS) and the value of myeloid nuclear differentiation antigen (MNDA). (2014) (2)
RARS-T Patients Harbor SF3B1 Mutations In 90.2% and Can Be Characterized By Mutations In ASXL1 and Other Spliceosome Genes In Most Of The Remaining Cases (2013) (2)
Cytogenetic and Molecular Genetic Characterization Of MLL-PTD Positive AML In Comparison To MLL-Translocated AML (2013) (2)
AKUTE LEUKAMIEN : PROGNOSTISCHE FAKTOREN UND THERAPIESTRATEGIEN (1999) (2)
The Two Mutation Hot Spots Ser34 and Gln157 in U2AF1 Show Different Occurrence, Correlation and Clinical Features in Myeloid Malignancies: An Analysis of 785 Cases (2012) (2)
Analysis for loss of heterozygosity on chromosome arm 13q by STR analysis or SNP sequencing can replace analysis of FLT3‐ITD to detect patients with prognostically adverse AML (2014) (2)
Benchmarking of Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) As Diagnostic Tools for the Genetic Characterization of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) in Adults (2021) (2)
Translocations Involving the IGH@ locus Occur In 3.7% of Chronic Lymphocytic Leukemia and Are Associated with Unmutated IGHV Status and a Shorter Time to Treatment: A Study on 2,135 Cases (2010) (2)
Whole genome sequencing demonstrates substantial pathophysiological differences of MYC rearrangements in patients with plasma cell myeloma and B-cell lymphoma (2021) (2)
In CML Patients with Good Response to TKIs Other Gene Mutations Are Frequently (37%) Present in Addition to Philadelphia Negative, Cytogenetically Aberrant Clones but Are Rare (4%) in Cases with MMR and Normal Karyotype (2014) (2)
IDH Mutations Can Be Detected In 28.7% of All Normal Karyotype AML and Have Unfavourable Impact on the NPM1+/FLT3-ITD- Genotype (2010) (2)
Detection of JAK2 Exon 12 Mutations in 10 Patients (10.1%) of V617F Negative PV: A Study of 211 Cases with PV or Suspected PV. (2007) (2)
MDS and AML With ≥15% Ring Sideroblasts Share Overlapping Features In Cytogenetics But Demonstrate Different Patterns and Incidences Of SF3B1 mutations (2013) (2)
Acute Lymphoblastic Leukemia (ALL) With Low-Hypodiploid/Near-Triploid Karyotype Is a Specific Clinical Entity Characterized By a High TP53 Mutation Frequency (2013) (2)
The Number of Cooperating Mutations in AML Is Still Growing: A Study on 3789 Patients. (2006) (2)
AML with Inv(3)(q21q26) or t(3;3)(q21;q26) Are Frequently Accompanied by Mutations in RUNX1 and NRAS and Show a High Incidence of NF1 Deletions: a Study On 40 Cases. (2009) (2)
Structured Information Processing as Enabler of Versatile, Flexible Manufacturing Concepts (2021) (2)
In Depth Characterization of CLL with Normal Karyotype By Array CGH and Mutation Screening (2015) (2)
Characterization of MDS Harboring TET2 Mutations and/or TET2 Deletions (2016) (2)
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study (2022) (2)
The RUNX1 Gene Is Altered in 26% of AML Patients Either By Translocation, Mutation, Gain or Deletion (2014) (2)
RUNX1 Mutations Reduce the Expression of CEBPA in Acute Myeloid Leukemia (2011) (2)
Somatic Mutations and Inborn Variants in Exon 12 of ASXL1 in Different Myeloid Neoplasms (2011) (2)
Challenging Blast Counts By Machine Learning Techniques and Genome Sequencing for Discriminating AML and MDS (2019) (2)
Comprehensive Analysis of MYC Translocations in Multiple Myeloma By Whole Genome Sequencing and Whole Transcriptome Sequencing (2019) (2)
AML and MDS Classification According to Who 2022 and International Consensus Classification: Do We Invent a Babylonian Confusion of Languages? (2022) (1)
Combined Impact of Aberrant Immunophenotypes, Somatic Mutations and Cytogenetic Aberrations on the Probability of Developing Myelodysplasia in Patients with Cytopenias of Undetermined Significance (2018) (1)
High Frequency of P53 Mutations Detected by a Microarray Resequencing Assay, the AmpliChip P53 Test, in AML with a Complex Aberrant Karyotype. (2006) (1)
T-Cell Acute Lymphoblastic Leukemia Can be Subdivided into Six Genetically Distinct Subtypes with Prognostic Impact By Combination of Whole Genome and Whole Transcriptome Data (2020) (1)
Complemental Prognostic Impact of Flow Cytometric and Molecular Quantification of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia (2019) (1)
How Whole Genome and Transcriptome Sequencing (WGTS) Can Contribute to Unsolved Cases in Hematology That Have Undergone Extensive Standard Diagnostic Workup: A Prospective Head-to-Head Study (2022) (1)
Molecular characterization of acute myeloid leukemia patients who relapse more than 3 years after diagnosis: an exome sequencing study of 31 patients (2019) (1)
SF3B1 Mutations in AML, MDS and MDS/MPN-RS-T Are Accompanied By Different Other Gene Mutations: Impact for Targeted Treatment Studies (2016) (1)
Specific Patterns of Molecular Mutations Determine the Morphologic Differentiation Stages in Acute Myeloid Leukemia (AML) (2014) (1)
A Comprehensive Cytogenetic and Molecular Genetic Characterization of Patients with T-PLL Revealed Two Distinct Genetic Subgroups and JAK3 Mutations As an Important Prognostic Marker (2014) (1)
Integration of clinical and genetic information - from patient data to gene expression analysis (2002) (1)
Excess Coincidences of Hematopoietic Neoplasms (2015) (1)
Molecular Screening Applying a Pan-Myeloid Gene Panel Reveals Mutations in All Patients with Acute Undifferentiated Leukemia (2014) (1)
Gene expression analyses in acute myeloid leukaemia (AML): current status and perspectives (2008) (1)
Acquired Imatinib Resistance in CML Is Associated with TKD Mutations of the BCR-ABL Fusion Gene and/or Additional Chromosomal Aberrations: Certain TKD Mutations but Not TP53 Mutations Are Associated with Chromosome Instability. (2008) (1)
Prognostic Value of “Monosomal Karyotype” in Comparison to “Complex Aberrant Karyotype” in AML: A Study on 824 Cases with Aberrant Karyotype (2011) (1)
Comparison of TP53 Alterations in Hematological Malignancies (2015) (1)
Targeted Next-Generation Sequencing (NGS) Enables a Broad Screening of 95 Molecular Mutations In a One-Step Approach and Detects Recurrent Mutations In AML with a Normal Karyotype In MYH11 and NOTCH1 (2010) (1)
Correlation of CD30 Expression on Neoplastic Mast Cells in Systemic Mastocytosis Assessed By Immunohistochemistry Versus Multiparameter Flow Cytometry and Correlation to Clinical Parameters (2015) (1)
Der(1;7)(q10;p10) Presents with a Unique Genetic Profile and Frequent ETNK1 Mutations in Myeloid Neoplasms (2021) (1)
The Number of RUNX1 Mutations and the Presence of One Intact RUNX1 Allele Influence Cytogenetic Abnormalities, Additional Molecular Mutations and Prognosis in RUNX1 Mutated AML (2016) (1)
Mutational Patterns and Correlation to Chip-Related Mutations in Hematological Malignancies - a Study on Mutation Frequencies of 122 Genes in 28 Entities Including 3096 Cases (2020) (1)
A 13-Gene Panel Targeted To Investigate CLL By Next-Generation Amplicon Deep-Sequencing Can Be Successfully Implemented In Routine Diagnostics (2013) (1)
Myeloid Nuclear Differentiation Antigen (MNDA) Expression: A Useful Marker in the Diagnosis of Myelodysplastic Syndromes By Flow Cytometry (2015) (1)
Two Novel Distinct Subtypes of Myeloid Neoplasms Molecularly Associated with Histone H3K36 Methylations (2015) (1)
The Outcome in AML Is Predicted by Cytogenetics, NPM1/FLT3 Mutation, Age and Sex, but Not by Treatment Variables. (2007) (1)
Cytogenetic Aberrations In Lymphoplasmacytic Lymphoma (LPL): A Study On 166 Cases (2010) (1)
Next-Generation Sequencing (NGS) in CMML, MDS and AML Detects Molecular Mutations in Oncogenes and Allows the Identification of Balanced Chromosomal Abnormalities with Extraordinary Sensitivity and Specificity. (2009) (1)
17p Deletion Is the Most Frequent Abnormality Acquired During Clonal Evolution in Chronic Lymphocytic Leukemia (CLL): 429 Cases Analyzed by Interphase FISH and Chromosome Banding Analysis, (2011) (1)
131I Tositumomab (2000) (1)
Impact of 9q Deletions on the Classification in AML (2017) (1)
All Clinically Relevant Leukemia Subtypes Can Be Diagnosed and Classified Based Solely on Gene Expression Profiling with an Accuracy of 95.1%: A Study on 1337 Adult Patients. (2004) (1)
Further Insights Into The Molecular Landscape Of De Novo Acute Myeloid Leukemia (AML) Investigating 1,291 Patients (2013) (1)
MDS and AML Are Closely Related Diseases: Gene Expression Patterns Reveal Clear Similarities with Respect to Karyotypes and Are Less Related to the Bone Marrow Blast Percentages. (2004) (1)
[Microarrays and gene expression profiling for the diagnosis in leukemia. From research studies to routine application]. (2006) (1)
Sensitive Monitoring of Minimal Residual Disease Status in CEBPA-Mutated Acute Myeloid Leukemia Using Amplicon Deep-Sequencing (2011) (1)
Flow Cytometric Findings Indicative of Myelodysplasia Differ Depending on the Karyotype (2008) (1)
Modulation of AraC by Fludarabine: Results of Salvage Therapy by AMLCG (2001) (1)
RUNX1 Mutations Play a Major Role in the Progression of MDS to S-AML Following MDS: A Genetic and Cytogenetic Analysis of Sequential Samples (2008) (1)
Mutation Screening at Diagnosis Reveals a High Frequency of ASXL1 Mutations in CML Patients Who Fail to Achieve Molecular Remission Criteria after One Year of TKI Treatment (2017) (1)
Aberrations identified by genomic arrays in normal karyotype CMML can be detected in 40% of patients, but do not add prognostic information to molecular mutations (2016) (1)
Whole Genome Sequencing in Hairy Cell Leukemia-Variant (HCL-v) and Splenic Marginal Zone Lymphoma (SMZL) (2017) (1)
FISH Analysis In 843 Cases with Myeloid Malignancies Revealed TET2 deletions In 6% of Patients Which Were Accompanied by TET2 Mutations In 51% of Cases (2010) (1)
The Impact of Homozygosity and Size of the 13q Deletion in Patients with CLL (2012) (1)
In CLL with Complex Aberrant Karyotype Distinct Entities Can Be Deciphered by Molecular Genetic and Cytogenetic Parameters (2008) (1)
61 Clinical impact of multiparameter flow cytometry in diagnosing myelodysplastic syndromes (2011) (1)
Flow Cytometric Identification of Biclonal Disease Among 5,523 Patients with Chronic Lymphocytic Leukemia and Its Genetic Characterization (2010) (1)
Does Age of Patients Influence the Composition of Gene Mutations in Myeloid Neoplasms (2015) (1)
Patients with Therapy-Related Myeloid Disorders Share Genetic Features but Can Be Separated by Blast Counts and Cytogenetic Risk Groups Into Prognostically Relevant Subgroups, (2011) (1)
A Comprehensive Deep-Sequencing Study of Blast Crisis Chronic Myeloid Leukemia (CML) Reveals New Insights Into Molecular Heterogeneity and Detects Mutations In 12 Different Genes In 82.5% of Cases (2010) (1)
Comparison of Mutation Patterns Between Diagnosis and Relapse in 444 Patients with Acute Myeloid Leukemia Shows High Variability of Stability and Influence On Time to Relapse (2012) (1)
Chromosome Banding Analysis Defines Subclasses of CLL with 13q14 Deletion and Identifies a New Mechanism of Submicroscopic 13q14 Deletions Occurring in the Breakpoint Region of Reciprocal Translocations. (2006) (1)
Correlation of Mutation Patterns with Patient Age in 2656 Cases with 11 Different Hematological Malignancies (2020) (1)
Prognostic relevance of FLT3-TED mutations in AML : the combination matters-an analysis of 3082 patients. Commentary (2008) (1)
Sequential Evolution Versus a Single Catastrophic Event (Chromothripsis) in the Pathogenesis of AML with Complex Aberrant Karyotype (2012) (1)
Impact of assay procedures on detection of MR4.5 status in chronic myeloid leukemia: Optimization of cDNA synthesis (2019) (1)
14 O - New mutation in BRCA 1 gene detected in 3 austrian HBOC families (1996) (1)
Detection of ABL1 kinase domain mutations in therapy-naïve BCR-ABL1-positive acute lymphoblastic leukemia (2021) (1)
Multiparameter Flow Cytometry in Patients with Suspected Myelodysplastic Syndromes Adds Significant Prognostic Information: A Study on 1,013 Patients (2011) (1)
Whole Genome Sequencing Identifies Microdeletions Affecting TET2 and RUNX1 with Clinical Impact in Myeloid Malignancies (2021) (1)
SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase (2022) (1)
Cyclin D1 ( CCND1 ) mRNA Expression Assessed by Real-Time PCR Is Increased in Patients with Mantle Cell Lymphoma and Contributes to Diagnosis in B-Cell Lymphoma Cases (2012) (1)
TP53 Mutations Are the Most Unfavorable Genetic Alteration in AML (2012) (1)
WGS and RNA-Seq Is Superior to Conventional Diagnostic Tests in Multiple Myeloma: Ready for Prime Time? (2018) (1)
TP53 Mutations Are Present In 15.7% Of ALL, Are Especially Frequent In ALL With MYC-Rearrangement and In ALL With Low Hypodiploid Chromosome Status and Are Associated With Poor Prognosis (2013) (1)
Next-Generation Deep-Sequencing Enables a Quantitative Monitoring of RUNX1 Mutations in 534 Patients with Myelodysplastic/Myeloproliferative Neoplasms and Myelodysplastic Syndromes (2011) (1)
Patients with TP53 Disruption and IGHV Mutated Status Show Indolent Clinical Course: A Study on 1,327 Treatment-Naive CLL Cases (2016) (1)
Multivariate Analysis of Prognostic Impact of Flow Cytometrically Determined Minimal Residual Disease in Patients with Acute Myeloid Leukemia. (2005) (1)
Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia (2021) (1)
Double Induction Containing Two Courses Versus One Course of High- Dose AraC/ Mitoxantrone (HAM) and Autologous Stem Cell Transplantation Versus Prolonged Maintenance for Acute Myeloid Leukemia (AML). (2005) (1)
P-051 Flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group (2013) (1)
Clinical Impact of Minimal Residual Disease (MRD) Monitoring in AML with PM-Rara, CBFB-MYH11, and RUNX1-RUNX1T1: A Study on 600 Patients (2015) (1)
Targeted Next-Generation Sequencing and Genome-Wide High-Resolution Copy Number DNA Arrays Allow the Identification of Five Novel RUNX1 Fusions In Hematological Malignancies. (2010) (1)
CSF3R Mutations Are Predominantly Subclonal Events in Intermediate Risk Karyotype AML and Prevalently Occur with CEBPA Mutations (2016) (1)
Array CGH Identifies Copy Number Changes In 10% Of 520 MDS Patients With Normal Karyotype: Deletions Encompass The Genes TET2, DNMT3A, ETV6, NF1, RUNX1, and STAG2 and Are Associated With Shorter Survival (2013) (1)
Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts (2022) (1)
Prospective Next-Generation Sequencing of Mutations in the ABL1 Kinase Domain in CML Patients Lacking Optimal Response According to ELN Guidelines (2016) (1)
Honoring Professor Franz Stelzer: four decades of inspiring research (2015) (1)
Robust and Sensitive Detection of Insertions, Deletions and Point Mutations In CEBPA, a GC-Rich Content Gene, Using 454 Next-Generation Deep-Sequencing (NGS). (2010) (1)
Gene Amplifications In 84 Patients With Acute Myeloid Leukemia and 31 Patients With Myelodysplastic Syndrome Investigated By Array CGH (2013) (1)
An Accumulation of Cytogenetic and Molecular Genetic Events Characterizes the Progression From MDS to Secondary AML: An Analysis of Paired Samples in 38 Patients Analyzed by Cytogenetics, Mutation Analysis and SNP Microarrays. (2009) (1)
Presentation and Diagnosis: Novel Molecular Markers and their Role in the Prognosis and Therapy of Acute Myeloid Leukemia (2011) (1)
Machine Learning Algorithm Correctly Identifies 95% of Cells in Differential Count of Blood Smears: A Prospective Study on >29,000 Cases and >17 Million Single Cells (2022) (1)
[Diagnosis of leukemia using microarray technology]. (2002) (1)
Whole Genome Sequencing Identifies Single Nucleotide Variants, Structural and Copy Number Abnormalities with a High Sensitivity in Hematological Neoplasm: An All in One Diagnostic Tool Tested on 3241 Cases (2018) (1)
TP53 Alterations In CLL - Parameters Influencing The Prognostic Impact: A Study On 3,988 Patients (2013) (1)
Acquisition of TP53 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients During the Course of Disease Is Associated with an Unmutated IGHV Status and Mutations in XPO1 and SF3B1 (2012) (1)
Characterization and Quantification Of Rare BCR-ABL1 Fusion Transcripts (2013) (1)
Multiparameter Flow Cytometry Identifies Dysplasia in Granulocytic, Monocytic, and Erythrocytic Lineages and Blasts in Patients with Myelodysplastic Syndromes: Correlation with Cytomorphology and Cytogenetics. (2004) (1)
Abstract 1514: Significance assessment of mutations in 944 MDS patients using publicly available variant databases and mutation impact prediction software (2016) (1)
Comprehensive Analysis Of U2AF1 Mutations In 843 Patients With Myeloid Neoplasms With Respect To Other Genetic Alterations (2013) (1)
[Immunophenotyping in modern leukemia diagnosis]. (2005) (1)
Rising Percentages of Blasts Are Associated with Continuously Increasing Frequencies of FLT3 -ITD and NPM1 Mutations In AML and In Addition Depend on Combinations of These Markers: Analysis of 805 Cases with Normal Karyotype AML. (2010) (1)
Aberrant Telomere Length and Composition Are Recurrent Features of Myeloid Disorders (2020) (1)
Application of RNA Sequencing Detects a Large Number of Novel Fusion Transcripts in Patients with AML and MDS (2019) (1)
Deletion 7q Is Associated with KLF2 and NOTCH2 Mutations and Is Strongly Correlated with Splenic Marginal Zone Lymphoma but Also Found in Lymphoplasmacytic Lymphoma and Hairy Cell Leukemia Variant (2017) (1)
CDKN1B Encoding the Cyclin-Dependent Kinase Inhibitor 1B (p27) but Not ETV6 Is Located in the Minimally Deleted Region of 12p Abnormalities in Myeloid Malignancies and Its Expression Is Associated with Outcome in Acute Myeloid Leukemia (AML). (2009) (1)
Molecular Screening In Blastic Plasmacytoid Dendritic Cell Neoplasms Reveals Mutations In TET2 and ASXL1 In The Majority Of Patients (2013) (1)
Applicability of DHPLC for Low Sensitive Residual Disease Detection in RUNX1 and CEBPA Mutated AML. (2009) (1)
Tyrosine Kinase Inhibitor Treated CML Patients Harboring Philadelphia-Negative Cytogenetically Aberrant Clones Show Molecular Mutations In 31% Of Cases Not Present At Diagnosis: A High-Throughput Amplicon Sequencing Study Of 29 Genes (2013) (1)
Specific subtype distribution with impact on prognosis of TP53 single hit and double hit events in AML and MDS. (2023) (1)
Mutations in CALR Are Associated with Del(13q) and Are Mutually Exclusive of Monosomy 7 in BCR-ABL1-Negative MPN (2014) (1)
FISH and WGS in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma - WGS Will Affect Future Treatment Decisions (2021) (1)
Employment of Machine Learning Models Yields Highly Accurate Hematological Disease Prediction from Raw Flow Cytometry Matrix Data without the Need for Visualization or Human Intervention (2020) (1)
RUNX1 Deletions Are a Novel Mechanism of Loss of Function in AML and Are Associated with Adverse Cytogenetics. (2012) (1)
Myeloid Malignancies With Isochromosome 17q Harbor Frequently Mutations In ASXL1, SETBP1, and SRSF2 - This Distinct Genotype Presents With Various Morphological Phenotypes (2013) (1)
In CLL with Normal Karyotype By Conventional and Genomic Array Karyotyping the Prognostic Impact of an Unmutated IGHV Status Is Stronger Than the Impact of Gene Mutations (2016) (1)
Cytogenetic and Molecular Genetic Clonal Evolution in CLL Is Associated with an Unmutated IGHV Status and Frequently Leads to a Combination of Loss of 17p and TP53 mutation (2016) (1)
A comprehensive approach to the diagnosis of MDS after triage by morphology towards cytogenetics and other techniques (2007) (1)
In Chronic Lymphocytic Leukemia the Gain of the Short Arm of Chromosome 2 Is Highly Associated with an Unmutated IGHV status, 11q/ATM Deletion, SF3B1 Mutation and a Complex Karyotype (2016) (1)
Types and Usage of Assembly Priority Charts in a Modular Assembly System (2018) (1)
The Use of Unique Molecular Identifiers (UMIs) Strongly Improves Sequencing Detection Limits Allowing Earlier Detection of Small TP53 Mutated Clones in Leukemias (2016) (1)
A Specific Gene Expression Signature Affecting the Beta-Catenin and Notch Signaling Pathways and the Downregulation of MALAT1 Prove Acute Myeloid Leukemia with Limited Differentiation (AML-LD) as a Distinct Entity with NPM1 Mutation. (2009) (1)
Comparative Assessment Of Minimal Residual Disease In Acute Myeloid Leukemia By Flow Cytometry and Molecular Genetics (2013) (1)
VIII. Internationales Symposium „Acute Leukemias”, Münster, 27.2.–3.3.99 Akute Leukämien Prognostische Faktoren und Therapiestrategien (1999) (1)
A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients (2015) (1)
P735: THE ROLE OF SF3B1 MUTATIONS IN MYELODYSPLASTIC SYNDROMES (2022) (1)
Evaluation of a Transparent Artificial Intelligence (AI) Disease Classification System with Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) Data in a Prospective Study with 325 Cases (2022) (1)
'Deep insight' into microarray technology (2011) (1)
Landmark Analyses of DNMT3A Mutations in Hematological Malignancies (2011) (1)
C009 Identification of dysplastic features in patients with myelodysplastic syndromes by multiparameter flow cytometry and correlation with cytomorphology and cytogenetics (2007) (1)
Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation (2022) (0)
Minimal Residual Disease Detection in Acute Myeloid Leukemia by RQ‐PCR and Multiparameter Flow Cytometry (2012) (0)
About 17% of AML with NPM1 mutations Show a Specific Pattern of Chromosome Aberrations but These Cases Do Not Differ Prognostically from AML with NPM1 Mutations Carrying a Normal Karyotype (2008) (0)
DNA Methylation and Genetic Profiles in 320 Patients with Myelodysplastic Syndromes (2018) (0)
Comprehensive Cytogenetic and Molecular Genetic Characterization of T-PLL Identifies for the First Time BCOR Mutations in a Lymphatic Disease. (2012) (0)
Proximally Biased V(D)J Recombination and Evolution of Non-Productive Clones in B-Cell Precursor Acute Lymphocytic Leukemia with KMT2A::AFF1 Fusion Genes (2022) (0)
Identification of a specific immunophenotype associated with a consistent pattern of genetic mutations including SRFS2 and gene expression profile in MDS (2019) (0)
A Completely Digital Workflow for Differentials in Bone Marrow Cytomorphology Supported By Machine Learning Provides Promising Results in Object Detection (2021) (0)
Multilineage Dysplasia Has No Prognostic Impact in 108 Adult Patients with CEBPA Mutated AML Supporting the WHO Proposal to Classify These Patients As A Molecularely Defined Unique Entity (2011) (0)
The Use of NGS for Molecular Investigations in Leukemia Adds Important Biological, Clinical and Prognostic Information Due to Its Higher Sensitivity in Comparison to the Gold Standard Sanger Sequencing (2016) (0)
Acute Lymphoblastic Leukemia (ALL) with Low-Hypodiploid/near Triploid Karyotype Is a Specific Clinical Entity with Poor Outcome (2012) (0)
Robustness of comprehensive DNA- and RNA-based assays at diagnosis of acute myeloid leukemia using blood and bone marrow stored on filter cards (2016) (0)
Detecting the Unusual without Compromising Diagnostic Accuracy - a Prospective WGS/Wts Pilot Study in Acute Leukemias Provided Additional Information for Diagnosis, Prognosis and Treatment (2022) (0)
Impact of the simultaneous administration of the (+)- and (−)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (−)-tetrahydrofolic acid (2000) (0)
Acute Myeloid Leukemia with Translocation t(8;16) Demonstrates Specific Cytomorphological, Cytogenetic, and Gene Expression Characteristics and Can Clearly Be Discriminated from Other AML with Balanced Translocations. (2004) (0)
ALL-144: Oncogenic Deregulation of BCL11B in Lineage Ambiguous Leukemia (2021) (0)
Interlaboratory Validation of a 3-Tube 10-Color Antibody Flow Cytometry Panel for Diagnosis of Myelodysplastic Syndromes (2012) (0)
Myelodysplastic Syndromes and Philadelphia Negative Chronic Myeloproliferative Diseases Show an Overlapping Pattern of Cytogenetic Aberrations. (2007) (0)
High-Throughput Sequencing to Identify Cytogenetic and Molecular Genetic Aberrations in 24 AML Exomes (2014) (0)
[Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)]. (2007) (0)
DNMT3A and NPM1 Double Mutated AML Is a Phenomenon of the Younger Patient and Could Represent a New Entity (2018) (0)
[Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis]. (2005) (0)
Acute Myeloid Leukemias Differ at Primary Diagnosis and Relapse in Endogenous Proliferative Activity, Response to Stimulation by Exogenous G-CSF and GM-CSF and Production of G-CSF (2003) (0)
Identification and Characterization of Potential Candidates for Treatment Targeting Apoptosis Pathways in Patients with Hematological Neoplasms (2018) (0)
Deletion of the Tumor Suppressor Gene NF1 Is An Alternative Mechanism for Aberrant Activation of the RAS Pathway and Is Found in 11% of Acute Myeloid Leukemia. (2009) (0)
Valve means for aeration and / or venting a tank for a motor vehicle, as well as tank system for a motor vehicle (2016) (0)
Use Of Flow Cytometry To Identify Myelodysplasia In Peripheral Blood (2013) (0)
Acute Myeloid Leukemia With t(8;21)/RUNX1-RUNX1T1 demonstrate a High Number Of Secondary Genetic Lesions: Frequency and Impact On Clinical Outcome (2013) (0)
The Investigation of Molecular Markers in the Prognostically Intermediate Karyotype Group in AML Provides Clinically Relevant Information. (2004) (0)
Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools (2022) (0)
Application of Multiparameter Flow Cytometry for the Identification of Dysplasia in Granulocytic, Monocytic, and Erythrocytic Lineages and Blasts in Patients with Myelodysplastic Syndromes. (2006) (0)
Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes (2022) (0)
Correlation Between Cytogenetic Aberrations Detected by Conventional Chromosome Banding Analysis and Specific Immunophenotypes in Patients with B-Cell Lymphoproliferative Diseases (2008) (0)
Identification and Characterization of Three Novel Cytogenetically Cryptic EVI1 Rearrangements Identified in 27 AML Patients All Predicting An Unfavorable Outcome (2011) (0)
Abstract LB-329: Enhancing the resolution and accelerating the pace of translational fusion characterization in oncology by RNA sequencing (2016) (0)
Using Whole Genome Sequencing (WGS) of 3256 Patients with Hematologic Malignancies to Determine Genome Instability (2018) (0)
14q Deletions Are Recurrent Aberrations in CLL and Other Mature B-Cell Neoplasms and Show a High Coincidence with An Unmutated IgVH Status and Trisomy 12, and Are Associated with An Intermediate Overall Survival and a Shorter Time to Treatment. (2009) (0)
Flow cytometry in the diagnosis of myelodysplastic syndromes (2022) (0)
Prognosis In Patients with MDS or AML and Bone Marrow Blasts Between 10% and 30% Is Not Associated with Blast Count but Depends on Cytogenetic and Molecular Genetic Parameters (2010) (0)
WT1 Expression as Follow up Marker in CML: Low Impact and Sensitivity Compared to BCR-ABL Specific RQ-PCR but High Impact for Detection of New Aberrant Clones in BCR-ABL Negative Follow up Samples (2008) (0)
In Myelodysplastic/Myeloproliferative Neoplasms Aberrant Antigen Expression As Assessed by Multiparameter Flow Cytometry Is Related to Molecular Genetic Mutations (2011) (0)
Molecular Evolution of Ccus Already Follows the Same Rules As MDS Progression (2022) (0)
RUNX1 Mutated AML and MDS: Similarities, Differences and Molecular Factors Leading to Disease Progression (2022) (0)
Comprehensive Molecular Analyses of BCR-ABL1 Negative MPN Show That PMF Is Genetically Much More Heterogeneous Than ET and PV (2014) (0)
The Evolution of Genetic Aberrations in CML Patients Harboring a Ph-Negative Clone: A 6-Year Follow-up Study of 52 Patients (2018) (0)
Methylation of the Proximal, Distal and Core Promoter of CEBPA in 574 Cases with Normal Karyotype AML and 44 with t(8;21) Disclosed Different Frequencies but No Impact on Prognosis (2011) (0)
Gene Expression Profiling Demonstrates Similar Biological Patterns in t-AML vs. de novo AML: A Study Including 106 Patients. (2004) (0)
Deep-Sequencing Of The Molecular Landscape In Burkitt Lymphoma/Leukemia (2013) (0)
Correction: How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing (2022) (0)
Complex Aberrant Karyotypes Are Associated with Dismal Prognosis in CLL: Chromosome Banding Analysis Provides Important Prognostic Information in CLL in Addition to Interphase-FISH (2008) (0)
Myelodysplastic Syndrome Patients Show Mutation-Specific DNA Methylation Patterns (2015) (0)
S886 CLASSIFICATION OF MYELOPROLIFERATIVE NEOPLASMS BASED ON DEEP LEARNING ALGORITHMS AND MOLECULAR GENETIC MARKERS SUPPORT DISTINCTION OF CML, PV, ET, AND PMF (2019) (0)
Gene Expression Profiling in Adult Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, and Acute Myeloid Leukemia M0: Confirmation of Immunophenotypic and Cytogenetic Diagnostic Findings. (2004) (0)
Mutant TP53 prevents Telomere Shortening in Acute Myeloid Leukemia (2021) (0)
Correction: complex landscape of alternative splicing in myeloid neoplasms (2021) (0)
Analysis of 12 Genes in 268 Cases with CMML Identifies ASXL1 Mutations As the Most Important Genetic Alteration Associated with Adverse Outcome (2012) (0)
Diagnostic challenge of identifying cases with recurrent t(8;14)(q24.21;q32.2) Involving BCL11B in acute leukemias of ambiguous lineage: an analysis of eight patients (2021) (0)
Chromosome Banding Analysis Allows a More Precise Classification of CLL Than Interphase FISH: A Study on 446 Cases. (2006) (0)
Incidential Findings of Mutations in the PIGA Gene Are Highly Specific for the Presence of PNH Clones (2021) (0)
Resistance to Drug-Induced Cytotoxicity in Acute Myeloid Leukemia is Significantly Correlated Between Inhibitors of Topoisomerases I and II and Nucleoside Analogues (2003) (0)
Targeting Genomic Heterogeneity of Adult Acute Lymphoblastic Leukemia (2014) (0)
In BCR-ABL1 Negative Myeloproliferative Neoplasms the Detection of JAK2exon12, MPLW515, CBL, KITD816V, FIP1L1-PDGFRA Mutations Are Closely Linked to Specific Entities, Whereas the JAK2V617F, TET2, or EZH2 Mutations Demonstrate a Broader Diversity: Patterns From Diagnostic Reports of 18,547 Patients (2010) (0)
FS-HAI for Relapsed AML (2003) (0)
the Impact of Clonal Dynamics on Prognosis and Outcome in Myelodysplastic Syndromes (2016) (0)
Time Points, Dynamics and Clinical Impact of Minimal Residual Disease (MRD) Monitoring in AML with NPM1 mutation: A Study on 428 Patients (2016) (0)
AML classification in the year 2023: How to avoid a Babylonian confusion of languages. (2023) (0)
Primary and Secondary Hematological Neoplasms - Are They Related? (2019) (0)
O-005 Mutations in U2AF1 highly associate with MDS-RAEB and del(20q) (2013) (0)
INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (2019) (0)
EZH2 Mutations Can Be Detected in 23% of t(10;11)(p13;q14)/PICALM-MLLT10 Positive Acute Leukemias, (2011) (0)
Automated Disease Classification Using Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) Data with Transparent Artificial Intelligence (AI) (2021) (0)
Occurrence of T-Lymphocytes with Aberrant Immunophenotypes Suggestive of Mature T-Cell Neoplasms In Patients with Hairy Cell Leukemia (2010) (0)
137 Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group (2011) (0)
Role of Screening for Molecular Mutations in Patients with Suspected MDS (2017) (0)
Molecular Analysis of RAS-RAF Tyrosine-Kinase Signaling Pathway Alterations in Multiple Myeloma (2011) (0)
Putative Germline Variants in the Predisposition Genes DDX41, ETV6 and GATA2 investigated in 1,228 Patients with Sporadic AML or MDS (2020) (0)
Characterization of Del(14)(q24q32) in Mature B-Cell Neoplasms By Array-CGH, Cytogenetics and Molecular Mutations (2015) (0)
Copy-Neutral Loss-of-Heterozygosity Adds Diagnostic and Prognostic Information to the Molecular Profiling of Hematological Malignancies (2021) (0)
Flow Cytometric Assessment of Myeloid Nuclear Differentiation Antigen (MNDA) Expression in Myelodysplastic Syndromes As a Diagnostic Marker (2011) (0)
A MAFB Associated Regulatory Network Distinguishes CMML from Other MDS/MPN Overlap Entities (2018) (0)
MDS subclassification—do we still have to count blasts? (2022) (0)
TP53 Mutations, Deletions, and CN-LOH: Comparison of TP53 single Hit and Double Hit Events and Their Impact on Prognosis in Hematological Malignancies (2021) (0)
Prognostic Impact of Cytogenetics and Early Response and Efficacy of Sequential High-Dose AraC and Idarubicin (S-HAI) in Patients with Refractory and Relapsed Acute Myeloid Leukemia (AML): Results of a Prospective Study. (2004) (0)
Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population: Analysis of the "Health and Anemia" Study (2018) (0)
Cracking a Nut with a Sledgehammer? - Broadening the Spectrum of Gene Mutation Analysis in MDS Does Not Add Clinically Relevant Information (2020) (0)
Prognostic Impact of Multiparameter Flow Cytometry in Patients Analyzed for Suspected MDS. (2012) (0)
O-006 SF3B1 mutations in MDS subgroups and s-AML and their association with cytogenetics and other molecular markers (2013) (0)
Cytogenetic and Molecular Genetic Shifts in 27 Genes Investigated By NGS Depict Specific Routes from MDS to s-AML in 38 Patients with Paired Samples (2014) (0)
Loss or Mutation of TP53 Is Highly Associated with Complex Aberrant Karyotype and Chromosomal Translocations in Chronic Lymphocytic Leukemia. (2006) (0)
Comprehensive Analysis of Mixed Phenotype Acute Leukemia (MPAL) By Whole Genome Sequencing (2017) (0)
Analysis For Loss Of 13q Heterozygosity Using STR Or SNP Analysis Can Replace Analysis Of FLT3-ITD To Detect Prognostically Adverse AML (2013) (0)
ETV6 Rearrangements Are Recurrent Genetic Events In Myeloid Malignancies and In AML Are Associated with NPM1- and RUNX1-Mutations and An Intermediate Prognosis (2010) (0)
ERG Overexpression Is Highly Associated With ERG Gene Amplifications In Patients With Myeloid Malignancies (2013) (0)
Mutations in the AML1 Gene Define an Unfavorable Subgroup in Acute Myeloid Leukemia with FAB M0. (2004) (0)
Molecular Characterization of Philadelphia Chromosome Positive Acute Myeloid Leukemia - New Provisional Entity? (2015) (0)
P-053 Characterization of 305 patients with myelodysplastic syndromes and 20q-deletion: Cytomorphological features, and concomitant cytogenetic and molecular genetic alterations (2013) (0)
Interphase FISH and Comparative Genomic Hybridization Performed in Addition to Chromosome Banding Analysis in AML with Normal Karyotype Detect Prognostically Relevant Chromosome Abnormalities. (2004) (0)
Prognosis of MDS Subtypes RARS, RCMD and RCMD-RS Does Not Differ by Cytomorphologic Criteria but Cytogenetics Allows to Delineate a Subgroup with Inferior Clinical Course, (2011) (0)
Comprehensive Genetic Analyses Of 213 PMF Patients Revealed 13% Of SRSF2 Mutations Being Strongly Correlated To ASXL1 Mutations (2013) (0)
Analysis of the Genetic Background in Patients with Myeloid Malignancies and Divergent Findings Regarding Blasts As Determined By Cytomorphology and Flow Cytometry (2019) (0)
Complete or Partial Deletions of IKZF1 Occur In 28% of Blast Crisis CML and Are the Only Recurrent Submicroscopic Alteration Associated with Disease Progression: An Analysis of 43 Cases Using High-Resolution Genome-Wide Copy Number DNA Arrays and Molecular Assays (2010) (0)
180 IMMUNOPHENOTYPIC ANALYSIS OF ERYTHROID DYSPLASIA IN MYELODYSPLASTIC SYNDROMES. A REPORT ON BEHALF OF THE INTERNATIONAL AND EUROPEAN LEUKEMIANET IMDS-FLOW WORKING GROUP (2015) (0)
Analyzing the Transcriptome Discovers up-Regulation of HOXA Genes in Patients with Myeloid Neoplasms and Isochromosome 17q and Mutations in ASXL1, SETBP1 and SRSF2 (2016) (0)
A Study on Paired Tissue Sequencing in Hematologic Diseases to Distinguish Somatic from Germline Sequence Variants in Routine Diagnostics (2016) (0)
Landscape of DNA Methylation and Genetic Profiles in 291 Patients with Myelodysplastic Syndromes (2015) (0)
Bench and bedside haematological malignancies Laurent Degos David C Linch (1999) (0)
Population Observations on Clonal Hematopoiesis – European Perspective (2019) (0)
PCR-Based MRD Detection in AML with Normal Karyotype or Other intermediate Risk Aberrations by the Use of FLT3-LM, NPM1-Mutations, MLL-PTD or WT1-Overexpression. (2006) (0)
Abnormalities Detected By Array CGH and Fluorescence in Situ Hybridization in AML with Normal Karyotype Lacking Mutations in NPM1, CEBPA, RUNX1 and MLL Partial Tandem Duplications Are Associated with Unfavorable Outcome (2015) (0)
RUNX1 Mutated AML Are Associated with a Distinct Pattern of Cytogenetic and Additional Molecular Genetic Abnormalities (2014) (0)
Comprehensive Molecular Profiling of T-Cell Acute Lymphoblastic Leukemia Identifies Mutations in 76 (97.4%) of 78 Patients (2011) (0)
Abstract 5788: Genomic and transcriptomic profiles of DNA damage response genes in acute myeloid leukemia (2022) (0)
NRAS Mutations in AML: Biology, Cytogenetics, and Prognostic Impact in 2502 Patients. (2005) (0)
Junctional Adhesion Molecule C (JAM-C) Constitutes a New Marker for the Differential Diagnosis of B Cell Lymphomas. (2009) (0)
Short communication Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia (2010) (0)
Immunostimulatory CpG-Oligonucleotide Activated Metaphase Cytogenetics Is Feasible in Routine Diagnostics of Chronic Lymphocytic Leukaemia and Reveals More Abnormalities Than Interphase FISH. (2005) (0)
Quantification of Minimal Residual Disease (MRD) in MLL-PTD Positive AML Can Be Used for Prognostication in AML with Normal Karyotype. (2004) (0)
Abstract 3275: Comparison of somatic variant interpretation results between human experts and automated classification using AMP/ASCO/CAP guidelines (2018) (0)
Microarray analysis and expression profiling (2004) (0)
The Incidence of TP53 Mutations Is Low in Leukemia Overall but High in the Subgroups with Complex Aberrant Karyotypes: A Study on 309 Cases. (2006) (0)
An Approach to Virtual Karyotyping for Unbalanced Rearrangements Based on Gene Expression Data. (2007) (0)
IDH2 mutations in Hematological Malignancies: Distribution, Hot Spots, Clonal Development and Identification of a Novel (cyto-)Genetically Defined Subgroup (2022) (0)
Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesis (2022) (0)
Detection and separation of the S-adenosylmethionine-decarboxylase inhibitor SAM486A in human plasma and urine by reversed-phase ion-pairing high-performance liquid chromatography. (2001) (0)
Evaluation of Analysis Strategy for Cytoplasmic Lineage-Associated Markers in Mixed-Phenotype Acute Leukemia (MPAL) As Devised By Who Classification 2022 (2022) (0)
Immunophenotyping in Myelodysplastic Syndromes (2013) (0)
A NUP98-NSD1 Fusion Gene Can Be Detected in a Small Subset of Adult AML Patients with Normal Karyotype (2011) (0)
Pattern of Chromosomal Aberrations and IgVH Mutation Status in Patients with Monoclonal B-Cell Lymphocytosis (MBL) (2008) (0)
TET2 Mutations Are Not Specific for Certain MPN Entities but More Likely Seem to Indicate Disease Progression. (2009) (0)
Whole Genome Sequencing Identifies Non-KIT Mutations and Cytogenetic Aberrations in Systemic Mastocytosis but Has Limited Sensitivity for Detection of KIT D816V (2021) (0)
The Type of Genetic Abnormalities Causing Loss of 5q Varies Between MDS and AML and Is Associated with Worse Prognosis in MDS (2012) (0)
Degree of Aberrant Antigen Expression in Myelodysplastic Syndromes Correlates with the Number of Molecular Mutations (2015) (0)
Benchmarking of Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) As Diagnostic Tools for Determining the Mutation Status of IGHV Genes in CLL (2022) (0)
How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing (2022) (0)
Targeted Next-Generation Sequencing Of 2,761 Genes Detects Copy Number States and Molecular Mutations In a Single Approach (2013) (0)
Impact of Trisomy 8 on Expression of Genes Located on Chromosome 8 in Different AML Subgroups. (2004) (0)
Flow Cytometric Characterization of Genetically Defined Subgroups of Chronic Lymphocytic Leukemia: Basis for the Comprehensive Definition of Prognostic Parameters. (2004) (0)
Development of Molecular Mutations during the Evolution of Therapy-Related MDS and Therapy-Related AML (2014) (0)
Detection of Dysplastic Features by Multiparameter Flow Cytometry in Myelodysplastic Syndromes in Relation to Cytomorphology and Cytogenetics. (2007) (0)
Microarrays Are a Robust Platform Suitable for Diagnostics. (2004) (0)
Ultra-Deep Sequencing Leads to Earlier and More Sensitive Detection of the TKI Resistance Mutation p.T315I in CML (2014) (0)
Gene Expression Profiling to Detect New Treatment Targets in Leukemia and Lymphoma: A Future Perspective (2019) (0)
Frequency and Prognostic Impact of CD8 Expression In 5,523 Patients with Chronic Lymphocytic Leukemia (CLL) In Relation to Chromosomal Aberrations, IGHV Mutational Status and ZAP-70 Expression. (2010) (0)
219 RELATION BETWEEN MOLECULAR MUTATIONS AND ABERRANTLY EXPRESSED ANTIGENS IN MYELODYSPLASTIC SYNDROMES (2015) (0)
Molecular Characterization of B-Cell Neoplasms Harboring MYC Translocations (2013) (0)
CML Patients with Philadelphia-Negative Clones Occurring During Treatment with Tyrosine Kinase Inhibitors Harbor Molecular Mutations Typical for MDS. (2012) (0)
Homozygosity of Mutated Calreticulin in Myeloproliferative Neoplasms By an Acquired Chromosome 19p UPD Is Associated with Deletions in the Long Arm of Chromosome 5 and SF3B1 Mutations (2016) (0)
Analysis of BRCA1 and BRCA2 Mutations and Gene Expression in Hematological Malignancies - Implications for Differential Involvement in Pathogenesis of Lymphoid Neoplasms (2018) (0)
Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues (2022) (0)
High Antileukemic Efficacy and Shortened Neutropenia of Dose-Dense Induction (Sequential-HAM Followed by Pegfilgrastim) in Primary Acute Myeloid Leukemia - Results of a Pilot Study of the German AML-CG. (2007) (0)
Impact of 1p Deletions in Myelodysplastic Syndromes and Secondary AML Arising from Myelodysplastic Syndromes (2016) (0)
Diagnostic Application of Immunophenotypic Analysis of Erythroid Dysplasia in Myelodysplastic Syndromes. a Report on Behalf of the European Leukemianet-IMDS-Flow Cytometry Working Group (2014) (0)
Translocation t(14;19)(q32;q13) Is a Rare Abnormality in CLL and Associated with Trisomy 12, an Unmutated IgVH Status and a Distinct Gene Expression Profile. (2007) (0)
Flow Cytometric Assessment of the T-Cell Receptor Vβ Repertoire Identifies Clonal T-Cell Populations with High Specificity and Sensitivity. (2012) (0)
Specific Molecular Mutations with Prognostic Relevance in AML with Normal Karyotype Are Also Associated with Outcome in AML with Aberrant Karyotype: A Study on 1981 Cases, (2011) (0)
Analysis of the IDH1G105 (SNPrs11554137) Polymorphism in 961 AML Patients and in a Large Cohort of 475 Healthy Controls (2011) (0)
Analysis with the LightCycler System® Identifies a Highly Significant Correlation between ZAP-70 mRNA Expression and Immunoglobulin Variable Heavy Chain Gene Mutational Status in Chronic Lymphocytic Leukemia. (2005) (0)
JAK2 Mutation Screening and Chromosome Analysis Are Necessary for a Comprehensive Diagnostic Work up in CMPD: A Study on 469 Cases. (2005) (0)
Using the PLASTIC Middleware for the Creation of Context-aware, Adaptive Mobile Services (2009) (0)
High BAALC Expression in Cytogenetically Normal Acute Myeloid Leukemia Strongly Correlates with Adverse Markers Such As RUNX1 mut, MLL -PTD and FLT3 -ITD and Is Useful for Disease Monitoring (2012) (0)
myeloid leukemia the tyrosine kinase inhibitor resistance mutation T315I in chronic Ultra-deep sequencing leads to earlier and more sensitive detection (2016) (0)
A Bird’s-Eye View on Polymer-Based Hydrogen Carriers for Mobile Applications (2022) (0)
High Frequency of AML1/RUNX1 Mutations in Specific Cytogenetic Subgroups in De Novo Acute Myeloid Leukemia. (2007) (0)
Clonal Progression during First Course of Chemotherapy in Acute Myeloid Leukemia Suboptimal Responders Heralds Reinduction Failure and Early Death (2017) (0)
Mutations In SETBP1 Occur In 3.1% Of De Novo AML and Show a Distinct Genetic Pattern That Highly Resembles Atypical CML (2013) (0)
Genome Data Allow in silico Pharmacogenetic Studies Using the Genetic Makeup of Both the Individual Patient As Well As the Disease (2019) (0)
Dose-Dense Induction (Sequential-HAM) in Primary Acute Myeloid Leukemia - A Pilot Study of the AML-CG. (2006) (0)
5q Deletions Can Be Identified Based on the Expression Level of 5q Genes: A Study on 49 Cases with MDS or AML Analysed in Parallel by Gene Expression Profiling and Genomic Arrays. (2006) (0)
AML with Translocation T(8;16) Shows Unique Cytomorphological, Cytogenetic, Molecular, and Prognostic Features and Therefore Qualifies as An Own Entity According to WHO Criteria. (2008) (0)
High Incidence of RAS Signalling Pathway Mutations in MLL–rearranged Acute Myeloid Leukemia (2012) (0)
Screening for Paroxysmal Nocturnal Hemoglobinuria (PNH) in Patients with Cytopenia and Suspected Myelodysplasia Using the Fluorochrome-Conjugated Derivative of Aerolysin, FLAER (2008) (0)
Novel Non-Coding, Coding and Structural Variants in Hairy Cell Leukemia from Whole Genome Transcriptome Sequencing (2022) (0)
Higher Percentages of Ring Sideroblasts and SF3B1 Mutations in Patients with AML Correlate with Mutations in TP53 and Adverse Cytogenetics, but Have No Independent Impact on Outcome (2015) (0)
Changes in the Hierarchy of Risk Factors with Older Age in De-Novo Acute Myeloid Leukemia (AML). (2006) (0)
Towards a Comprehensive Prognostic Score in CLL Based On a Combination of Genetic Parameters. (2009) (0)
A Fully Automated Digital Workflow for Assessment of Bone Marrow Cytomorphology Based on Single Cell Detection and Classification with AI (2022) (0)
Ultra-Deep Next-Generation Sequencing (NGS) Detects BCR-ABL1 Kinase Domain Mutations with High Sensitivity and Allows to Monitor the Composition of Distinct Subclones During Tyrosine Kinase Inhibitor Treatment (2010) (0)
Impact of Expression of BAALC , CDKN1B, ERG , EVI1 , and MN1 on Prognosis and Their Association with Karyotype, FLT3 -ITD, NPM1 and MLL -PTD Status In Adult AML: A Comprehensive Study on 286 Cases (2010) (0)
Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesis (2022) (0)
Genexpressionsanalysen bei akuten Leukämien: Diagnostik der Zukunft? / Gene expression profiling in acute leukemia: diagnostics of the future? (2004) (0)
P744: UNBALANCED TRANSLOCATION DER(1;7)(Q10;P10) AS A DISTINCT SUBTYPE IN MYELODYSPLASTIC SYNDROMES (2022) (0)
Comprehensive Analysis of 22 Cases with Blastic Plasmacytoid Dendritic Cell Neoplasm Reveals Mutations in DNA Repair Genes and Two Distinct Subgroups Defined By Differential Gene Expression with Prognostic Impact (2019) (0)
Acute myeloid leukemia displaying clonal instability during treatment: implications for measurable residual disease assessments. (2022) (0)
Clinical Relevance of Concomitant Gene Mutations in CEBPA Double-Mutated Acute Myeloid Leukemia. (2012) (0)
Application of a Flow Cytometric Core Marker Set in the Diagnostic Workup of Patients with Suspected Myelodysplastic Syndromes (2022) (0)
Automated Comprehensive Diagnostics of Hematologic Neoplasms By Artificial Intelligence Models Using Flow Cytometric Raw Matrix Data (2021) (0)
The Gene Expression Profile in CLL Better Reflects the Igvh-Mutational Status Than the Most Common Chromosome Aberrations. (2004) (0)
The diverse landscape of fusion transcripts in 25 different hematological entities (2020) (0)
5q Deletions in MDS and MPN: The Accompanying Molecular Mutations Determine the Phenotype but TP53 Is Frequently Mutated in All Entities: MPN, MDS and MPN/MDS Overlap (2014) (0)
Gene Expression Profiling by Microarrays: Gene expression profiling for the diagnosis of acute leukemias (2006) (0)
The Detection of Multilineage Dysplasia (MLD) Has No Influence on Prognosis in NPM1 Mutated Acute Myeloid Leukemia (AML) with Normal Karyotype (2008) (0)
Applicability of FLT3-Length Mutations in Exon 14 as a Follow up Marker in AML: An Experience of 148 Cases and 517 Follow up Samples Using Conventional and Real Time PCR. (2004) (0)
Comprehensive Biologic Characterization of 99 Multiple Myeloma Patients Using Cytomorphology, FISH, Gene Expression Profiling and Mutation Screening Leads to Important Clinical and Therapeutic Insights (2016) (0)
Comprehensive Analyses of Mantle Cell Lymphoma with a 17 Gene Panel Reveal an Accumulation of TP53 Mutations in SOX11 Negative Patients (2014) (0)
PS922 BENEFITS OF RNA SEQUENCING IN DETECTING RECURRENT AND NOVEL FUSION TRANSCRIPTS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (2019) (0)
Issue Highlights – September 2019 (2019) (0)
Molecular Analysis of Myelodysplastic Syndrome with Isolated Del(5q) Reveals a Broad Spectrum of Clinically Relevant Mutations: A Study on 119 Patients and 26 Genes (2014) (0)
Evaluation of BRAF V600E, NRAS and KRAS Mutations As Well As IGHV Usage for Diagnostic Use in Hairy Cell Leukemia, Hairy Cell Leukemia-Variant and Splenic Marginal Zone Lymphoma. (2012) (0)
A Distinct Pattern of Additional Aberrations and Novel Mechanisms of MLLRearrangements Are Detectable in AML with 11q23 Aberrations Using SNP Arrays (2008) (0)
MYC Translocations In Mature B-Cell Neoplasms: Single, Double, Triple and Quadruple Hit Lymphoma (2013) (0)
Use of 5-Fold Staining for Multiparameter Flow Cytometry-Based Quantification of Minimal Residual Disease in Acute Myeloid Leukemia Results in Improved Sensitivity. (2004) (0)
Whole Genome Sequencing and RNA Sequencing of 27 Patients with Persistent Polyclonal B-Cell Lymphocytosis Reveals a High Mutation Frequency/Overexpression of Lymphoma Associated Genes: Really a Benign Disorder? (2018) (0)
Characterization and Prognostic Impact of Multiple Productive IGHV Rearrangements in CLL (2016) (0)
Development and validation of a real-time quantification assay to detect and monitor BRAF V 600 E mutations in hairy cell leukemia (2012) (0)
Array Based Comparative Genomic Hybridization Detects Copy Number Alterations in 80.3% of Adult Acute Lymphoblastic Leukemia (ALL) with Normal Karyotype or Failed Chromosome Banding Analysis and Identifies a Subset with Only Submicroscopic Alterations Associated with Favorable Outcome (2014) (0)
WT1 Mutations Are Secondary Events In AML and Show Varying Frequencies Within Genetic Subgroups and Different Impact On Prognosis (2013) (0)
Risk Stratification In Chronic Lymphocytic Leukemia Patients With IGHV3-21 Gene Usage According To Presence Of Stereotypy and Mutations In SF3B1 (2013) (0)
Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10) (2022) (0)
Targeted Next-Generation Sequencing (NGS) Enables for the First Time the Detection of Point Mutations, Molecular Insertions and Deletions, as Well as Leukemia-Specific Fusion Genes in AML in a Single Procedure. (2009) (0)
transcripts CBFBMYH11+ acute myeloid leukemia based on quantification of fusion New score predicting for prognosis in PML-RARA+, AML1-ETO+, or (2013) (0)
The Presence of Multilineage Dysplasia (MLD) Has No Significant Impact On Biological, Clinico-Pathological, and Prognostic Features in AML with Mutated Nucleophosmin (NPM1). (2009) (0)
P040 Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetic, and clinical data (2009) (0)
Identification of Phenotypic Subgroups of Acute Myeloid Leukemia, Defined By Differentiation According to Who 2022 Classification (2022) (0)
BAALC Expression Is a Feasible Marker for Risk Stratification and Detection of Minimal Residual Disease in Cytogenetically Normal Acute Myeloid Leukemia (2015) (0)
Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy (2022) (0)
Acute Monoblastic/Monocytic Leukemia and Chronic Myelomonocytic Leukemia Share Common Immunophenotypic Features but Differ in the Extend of Aberrantly Expressed Antigens and the Amount of Granulocytic Cells. (2009) (0)
NEW ENHANCED PROVEN® A SNEAK PEEK INTO PRESSURE REGULATION OF COKE OVEN CHAMBERS FOR EMISSION CONTROL (2014) (0)
NPM1 Mutated AML Is Characterized By Pre-Leukemic Mutations and the Persistence and Acquisition of Co-Mutations in Molecular Remission Leads to Inferior Prognosis (2018) (0)
Chronic Myeloproliferative Disorders (2012) (0)
Correlation of Multiparameter Flow Cytometry and Fluorescence In Situ Hybridization in Quantifying Malignant Cells at Low Frequencies in B-Cell Lymphoproliferative Diseases. (2007) (0)
Molecular Characterization of Acute Myeloid Leukemia (AML) Patients Who Relapse More Than 3 Years after Diagnosis: An Exome Sequencing Study of 31 Patients (2018) (0)
131I tositumomab: a viewpoint by Wolfgang Kern. (2000) (0)
comments) rare variant with a propensity for unusual sites of involvement (see Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a (2011) (0)
CBL Mutations Are Correlated with CMML, Frequently Associated with RUNX1 but Mutually Exclusive of JAK2V617F Mutations. (2009) (0)
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies. (2023) (0)
Complexity of CEBPA Mutated Acute Myeloid Leukemia (2014) (0)
Analysis of Philadelphia Negative Clones Detected during Treatment with Tyrosine Kinase Inhibitors: A Study on 63 CML Cases. (2007) (0)
NPM1 Mutated AML Can Relapse with Wildtype NPM1 and Evolve with Novel Mutations: Implications for Pathobiology and MRD Monitoring (2017) (0)
Landscape of TET2 Mutations In Acute Myeloid Leukemia (AML): A Next-Generation Sequencing Study Investigating 76 Cases Comprehensively Characterized for Cytogenetics and Other Molecular Markers. (2010) (0)
Co-Occurrence of Separate BCR-ABL1-Positve and JAK2V617F-Positive Clones in 23 Patients Reveals Biologic and Clinical Importance (2014) (0)
The Landscape of RUNX1 Mutations in Acute Myeloid Leukemia: Investigations On Stability of Mutations At Relapse and Utility As a Marker for Minimal Residual Disease (2012) (0)
BCL-2 Inhibition by ABT-199 Potently Induces Cell Death in MDS Progenitors Despite High-Risk Mutations in ASXL1, RUNX1, TP53 or EZH2 (2017) (0)
Long Intergenic Non-Coding RNAs Unambiguously Classify AML Subgroups (2018) (0)
Response to Imatinib Mesylate In CML Patients as Assessed by Quantitative Real Time PCR Can Predict the Probability for Resistance Mutations In the BCR-ABL1 Kinase Domain. (2010) (0)
B-Cell Scaffold Protein with Ankyrin Repeats (BANK1) Is Differentially Expressed in ZAP-70 Negative Compared to ZAP-70 Positive Chronic Lymphocytic Leukemia Cells. (2005) (0)
B-Cell Lymphoproliferative Disorders with t(11;14)(q13;q32) or t(14;18)(q32;q21) Can Be Subdivided into 4 Distinct Categories Based on Their Pattern of Additional Cytogenetic Aberrations and Antigen Expression. (2007) (0)
Analysis of Genetic Variants and Expression Levels of Human Organic Cation Transporter 1 (HOCT1) and Genetic Variants in MDR1 in CML: Weak Associations Were Detected but a Major Role in Clinical Response to Imatinib Resistance Is Unlikely (2008) (0)
Landscape of Secondary Genetic Lesions in Acute Myeloid Leukemia with Inv(16)/CBFB-MYH11 (2015) (0)
Comprehensive Investigation of 225 Patients with Myeloid Malignancies and Erythroid Hyperplasia (≥50%) Demonstrates That Acute Erythroid Leukemia (AEL, according WHO Classification 2008) Differs Significantly From MDS but Overlaps with Other AML Subtypes and Pure AEL Regarding Clinical and Genetic F (2010) (0)
PS1327 PRO-NECROPTOTIC RIPK3 AS A STAGE-DEPENDENT MARKER IN THE BONE MARROW OF PATIENTS WITH MDS AND CMML (2019) (0)
Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial (2011) (0)
NPM1 Mutations Have a High Impact On the Development of Secondary AML. (2009) (0)
Coincidence of JAK2V617F and BCR-ABL Is a Very Rare Event: Identification of 4 among 2317 Cases with Suspected CMPD. (2007) (0)
Characterization of CMML with Normal Karyotype in Comparison to CMML with Aberrant Karyotype (2015) (0)
Similar Patterns of Chromosome Abnormalities in CML Occur in Addition to the Philadelphia Translocation with or without Tyrosine Kinase Inhibitor Treatment. (2009) (0)
Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (2021) (0)
Risk prediction in MDS: independent validation of the IPSS-M—ready for routine? (2023) (0)
Granulocyte Colony-Stimulating Factor Improves the Antileukemic Efficacy of the Sequential High-Dose Cytosine Arabinoside and Mitoxantrone Regimen (S-HAM) in Patients Younger than 60 Years with High-Risk Acute Myeloid Leukemia (1998) (0)
IKZF1 deletions Are Detected In 40.3% Of 270 Adult B-Precursor-ALL and Are Independently Associated With BCR-ABL1 Positivity and Inferior Outcome (2013) (0)
Cytogenetic Aberrations In Splenic Marginal Zone Lymphoma (SMZL): A Study On 134 Cases (2010) (0)
Investigation Of Seven Genes Commonly Deleted In 271 Adult ALL Patients: Association With Cytogenetics and Clinical Features (2013) (0)
The FLT3-D324N Variant Is a Functionally Silent Polymorphism in the FLT3 Gene and May Be Associated with a Higher Risk for AML. (2004) (0)
Preview : Published ahead of advance online publication WT 1 mutations are secondary events in AML , show varying frequencies and impact on prognosis between genetic subgroups (2014) (0)
A Comprehensive Panel of Molecular Mutations Notably Improves a Cytogenetic Prognostication System in Routine AML Diagnostics (2016) (0)
Short communication Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia (2007) (0)
Therapy-Related Myeloid Neoplasms (tMN) Following Treatment of Acute Myeloid Leukemia (AML): Exome Sequencing Reveals the Presence of an Ancestral Clone Refractory to Chemotherapy (2018) (0)
Biology Based Treatment Strategies for Acute Myeloid Leukemia (2003) (0)
STATE-OF-THE-ART COKE OVEN PLANT CONCEPT – MAIN TECHNOLOGICAL ASPECTS (2022) (0)
Further Insights into the Pathogenesis of AML with Complex Aberrant Karyotype by Performing a Combination of Conventional CGH, Gene Expression and Genomic Array Analysis. (2005) (0)
Significance of Flow Cytometric and Mutational Findings in Patients with Cytopenias and Limited or No Signs of Myelodysplasia By Cytomorphology (2015) (0)
Prognostic Impact of NOTCH1 Mutations in Chronic Lymphocytic Leukemia (CLL): A Study On 538 Patients. (2012) (0)
Mathematical Modeling and Comparisons of Relapse Patterns in AML with 11q23/ MLL translocations and Normal Karyotype AML with MLL -PTD (2011) (0)
Myeloid Neoplasms with MYC-Positive Double Minutes, a Specific Subgroup? (2022) (0)
Targeted RNA Sequencing Is Capable of Identifying Thus Far Unknown Partner Genes in Leukemias with Rare Translocations and Provides Important Clinical and Therapeutical Information (2016) (0)
AML with RUNX1 Mutations and Loss of RUNX1 Wild-Type - a Distinct Subset? (2015) (0)
Comparison Of Mutation Patterns Between Diagnosis and Relapse In 556 Adult Patients With AML Shows High Variability Of Stability (2013) (0)
Correlation of Cytomorphology, Immunophenotyping, and Interphase Fluorescence in Situ Hybridization (FISH) in 381 Patients with MGUS and 310 Patients with Multiple Myeloma. (2009) (0)
MODERN COKE OVEN GAS TREATMENT TECHNOLOGY AT A NEW COKE MAKING PLANT IN BRAZIL (2017) (0)
The Recently Suggested MDS/MPN Subgroup “Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis (RARS-T)” Demonstrates Unique Clinical, Cytogenetic, and Molecular Aspects: A Comprehensive Analysis of 57 Cases Strictly Defined According to WHO Criteria (2010) (0)
Intensification of Induction by High-Dose AraC and Outcome in Older Patients with De-Novo Acute Myeloid Leukemia (AML) and Subsets. (2006) (0)
Significance Assessment of Mutations in MDS Patients Using Publicly Available Databases: A Study with 944 Samples and 6 Most Significantly Mutated Genes (2015) (0)
Assessment of CD30 expression on mast cells in systemic mastocytosis by immunohistochemistry versus multiparameter flow cytometry and correlation to clinical parameters (2016) (0)
Serial Assessment of Patients with Suspected Myelodysplastic Syndromes: Significance of Flow Cytometric Findings As Validated by Cytomorphology, Cytogenetics, and Molecular Genetics (2011) (0)
Abstract 2707: Targeted RNA sequencing reveals thus far unknown diagnostically relevant fusion partners confirming its diagnostic potential (2017) (0)
FOS Expression Distinguishes Two Groups of Atypical CML (aCML) Allowing Targeted Therapy (2018) (0)
Whole Genome Sequencing in Routine Hematologic Samples: How to Proceed Analyses Best When Germline Controls Are Missing? (2018) (0)
The Prognostic Impact of High EVI1 expression In AML Is Due to Its Close Correlation to Rearrangements Involving EVI1 or MLL, which Are Cytogenetically Cryptic In a Subset of Patients : a Study on 332 Cases. (2010) (0)
Microarray Analysis Detects Unique Expression Pattern for NPM1-Mutated AML with Normal Karyotype and Reveals Pathobiological Insights. (2007) (0)
“STATE-OF-THE-ART” COKING TECHNOLOGIES. CHALLENGING EMISSIONS AT THE SERVICE OF THE ENVIRONMENT: A PRACTICAL BRAZILIAN EXAMPLE (2014) (0)
CLL-156: Novel CCL22 Mutations Drive Chronic Lymphoproliferative Disorder of NK Cells Through Biased GPCR Signaling (2021) (0)
Leveraging Whole Genome Sequencing to Define the Mutational Landscape in Paroxysmal Nocturnal Hemoglobinuria (2020) (0)
Impact of FLT3 Mutation Status and Other Genetic Parameters In Acute Promyelocytic Leukemia (APL) with t(15;17)(q22;q12)/PML-RARA. (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Wolfgang Kern?

Wolfgang Kern is affiliated with the following schools:

Humboldt University of Berlin
University of Cologne
Technical University of Berlin

Wolfgang Kern's Academic­Influence.com Rankings

Why Is Wolfgang Kern Influential?

Wolfgang Kern's Published Works

Published Works

What Schools Are Affiliated With Wolfgang Kern?

Wolfgang Kern's AcademicInfluence.com Rankings